<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1514</article-id><article-id pub-id-type="doi">10.36691/RJA1514</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Elimination of participants in the allergy mechanism: elimination of homeostasis mechanisms? New approaches to the treatment of allergies</article-title><trans-title-group xml:lang="ru"><trans-title>Устранение участников механизма аллергии ― устранение механизмов гомеостаза? Новые подходы к лечению аллергии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4465-6509</contrib-id><contrib-id contrib-id-type="spin">1905-4758</contrib-id><name-alternatives><name xml:lang="en"><surname>Gushchin</surname><given-names>IIgor S.</given-names></name><name xml:lang="ru"><surname>Гущин</surname><given-names>Игорь Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor, Corresponding member of Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корр. РАН</p></bio><email>igushchin@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2397-5172</contrib-id><contrib-id contrib-id-type="spin">4004-6561</contrib-id><name-alternatives><name xml:lang="en"><surname>Khaitov</surname><given-names>Rakhim M.</given-names></name><name xml:lang="ru"><surname>Хаитов</surname><given-names>Рахим Мусаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor, Academician of Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>rkhaitov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia</institution></aff><aff><institution xml:lang="ru">Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентства</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-02-07" publication-format="electronic"><day>07</day><month>02</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-04-06" publication-format="electronic"><day>06</day><month>04</month><year>2022</year></pub-date><volume>19</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>11</fpage><lpage>42</lpage><history><date date-type="received" iso-8601-date="2022-01-17"><day>17</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-01-24"><day>24</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Фармарус Принт Медиа</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-04-06"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/1514">https://rusalljournal.ru/raj/article/view/1514</self-uri><abstract xml:lang="en"><p>The participation of an allergic reaction and its main constituent elements (IgE, mast cells/basophils, and eosinophils) in maintaining various types of homeostatic function is becoming increasingly obvious. This is illustrated by the example of such evolutionary acquisitions as antiparasitic and antitumor types of resistance of the organism of highly organized animal species. All three participants in the allergic reaction are involved in the preservation of the mechanisms of these forms of homeostasis, from which follows the frequently expressed fear that prolonged maintenance of the blockade of the activity of these participants. Even more so, their elimination may be accompanied by undesirable consequences in the form of suppression of specific homeostasis mechanisms, which should be taken into account when introducing into clinical practice of new groups of antiallergic drugs focused on long-term and even lifelong use.</p> <p>The appeal to the development and use of antiallergic agents that eliminate the participants in the allergic response, acquired in the course of evolution and performing homeostatic functions, rather stems from the hopelessness of the situation in the treatment of patients with a severe course of the disease who are resistant to other methods of antiallergic therapy. Understanding and acceptance of such a concept in the scientific community can serve as an impetus for the improvement of existing and the creation of fundamentally new and strategically justified methods of preventing <bold>not the very possibility</bold> but <bold>the need for</bold> the development of an allergic response. Today, such methods are the restoration of the usefulness of barrier systems, allergen-specific immunotherapy, and use of natural methods to limit, stop, and reverse development (resolution) of an allergic reaction.</p></abstract><trans-abstract xml:lang="ru"><p>Участие аллергической реакции и её главных составляющих элементов (IgE, тучные клетки/базофилы, эозинофилы) в поддержании разных видов гомеостатической функции в настоящее время становится всё более очевидным, что проиллюстрировано на примере таких эволюционных приобретений, как противопаразитарный и противоопухолевый способы устойчивости организма высокоорганизованных видов животных. В сохранение механизмов этих форм гомеостаза вовлекаются все три участника аллергической реакции, откуда следует всё более часто высказываемое опасение, что длительное поддержание блокады активности этих участников и тем более их устранение может сопровождаться нежелательными последствиями в виде подавления специфических механизмов гомеостаза. Это следует учитывать при внедрении в клиническую практику новых групп противоаллергических средств, ориентированных на длительное, а то и пожизненное применение.</p> <p>Обращение к разработке и использованию противоаллергических средств, устраняющих участников аллергического ответа, приобретённых в ходе эволюции и выполняющих гомеостатические функции, происходит, скорее, от безысходности положения при лечении пациентов с тяжёлым течением заболевания, устойчивым к другим методам противоаллергической терапии. Понимание и принятие такого представления в научном сообществе может послужить толчком к совершенствованию существующих и созданию принципиально новых и стратегически оправданных методов предотвращения <bold>не самой возможности, а необходимости</bold> развития аллергического ответа. На сегодняшний день такими методами являются восстановление полноценности барьерных систем; аллергенспецифическая иммунотерапия; использование естественных способов ограничения, остановки и обратного развития (разрешения) аллергической реакции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>allergy</kwd><kwd>homeostasis</kwd><kwd>IgE</kwd><kwd>FcεRI</kwd><kwd>mast cells</kwd><kwd>eosinophils</kwd><kwd>antiparasitic resistance</kwd><kwd>antitumor resistance</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аллергия</kwd><kwd>гомеостаз</kwd><kwd>IgE</kwd><kwd>FcεRI</kwd><kwd>тучные клетки</kwd><kwd>эозинофилы</kwd><kwd>противопаразитарная устойчивость</kwd><kwd>противоопухолевая устойчивость</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Ado AD. General allergology (a guide for doctors). 2nd ed., revised and updated. Moscow: Medicine; 1978. 464 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Адо А.Д. Общая аллергология (руководство для врачей). 2-е изд., перераб. и доп. Москва: Медицина, 1978. 464 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Khaitov RM. Immunology: textbook. 4th ed., revised and updated. Moscow: GEOTAR-Media; 2021. 520 р. (In Russ). doi: 10.33029/9704-6398-7-IMM-2021-1-520</mixed-citation><mixed-citation xml:lang="ru">Хаитов Р.М. Иммунология: учебник. 4-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2021. 520 с. doi: 10.33029/9704-6398-7-IMM-2021-1-520</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. On the elements of biological expediency of allergic reactivity. Patholog Physiol Experiment Ther. 1979;(4):3–11. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С. Об элементах биологической целесообразности аллергической реактивности // Патологическая физиология и экспериментальная терапия. 1979. № 4. С. 3–11.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. Evolutionary warning: allergy. Patholog Physiol Experiment Ther. 2014;58(1):57–67. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С. Эволюционное предупреждение: аллергия // Патологическая физиология и экспериментальная терапитя. 2014. Т. 58, № 1. С. 57–67.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. Allergy ― late product of the immune system evolution. Immunology. 2019;40(2):43–57. (In Russ). doi: 10.24411/0206-4952-2019-12007</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С. Аллергия ― поздний продукт эволюции иммунной системы // Иммунология. 2019. Т. 40, № 2. С. 43–57. doi: 10.24411/0206-4952-2019-12007</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS, Kurbacheva OM. Allergy and allergen-specific immunotherapy. Moscow: Pharmarus Print Media; 2010. 228 р. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. Москва: Фармарус Принт Меди, 2010. 228 с.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. Tissue barrier permeability to allergtn ― strtategic problem of allergology. Pulmonology. 2006;(3):5–13. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С. Алергенная проницаемость барьерных тканей ― стратегическая проблема аллергологии // Пульмонология. 2006. № 3. С. 5–13.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. Receptors of specialized pro-resolving mediators ― a probable target of pharmacological restoration of homeostasis in allergic inflammation. Immunology. 2021;42(3):277–292. (In Russ). doi: 10.33029/0206-4952-2021-42-3-277-292</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С. Рецепторы специализированных проразрешающих медиаторов ― вероятная мишень фармакологического восстановления гомеостаза при аллергическом воспалении // Иммунология. 2021. Т. 42, № 3. С. 277–292. doi: 10.33029/0206-4952-2021-42-3-277-292</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Tan HT, Sugita K, Akdis CA. Novel biologicals for the treatment of allergic diseases and asthma. Curr Allergy Asthma Rep. 2016;16(10):70. doi: 10.1007/s11882-016-0650-5</mixed-citation><mixed-citation xml:lang="ru">Tan H.T., Sugita K., Akdis C.A. Novel biologicals for the treatment of allergic diseases and asthma // Curr Allergy Asthma Rep. 2016. Vol. 16, N 10. P. 70. doi: 10.1007/s11882-016-0650-5</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Curr Opin Immunol. 2009;21(6):708–714. doi: 10.1016/j.coi.2009.09.010</mixed-citation><mixed-citation xml:lang="ru">Karra L., Berent-Maoz B., Ben-Zimra M., Levi-Schaffer F. Are we ready to downregulate mast cells? // Curr Opin Immunol. 2009. Vol. 21, N 6. P. 708–714. doi: 10.1016/j.coi.2009.09.010</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Siebenhaar F, Redegeld FA, Bischoff SC, et al. Mast cells as drivers of disease and therapeutic targets. Trends Immunol. 2018;39(2):151–162. doi: 10.1016/j.it.2017.10.005</mixed-citation><mixed-citation xml:lang="ru">Siebenhaar F., Redegeld F.A., Bischoff S.C., et al. Mast cells as drivers of disease and therapeutic targets // Trends Immunol. 2018. Vol. 39, N 2. P. 151–162. doi: 10.1016/j.it.2017.10.005</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Schanin J, Gebremeskel S, Korver W, et al. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunol. 2021;14(2):366–376. doi: 10.1038/s41385-020-00336-9</mixed-citation><mixed-citation xml:lang="ru">Schanin J., Gebremeskel S., Korver W., et al. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation // Mucosal Immunol. 2021. Vol. 14, N 2. P. 366–376. doi: 10.1038/s41385-020-00336-9</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Kay AB, Bousquet J, Holt PG, Kaplan AP, ed. Allergy and Allergic Diseases, 2 Volume Set. 2nd ed. New York: Wiley-Blackwell; 2008. 2184 р.</mixed-citation><mixed-citation xml:lang="ru">Kay A.B., Bousquet J., Holt P.G., Kaplan A.P., ed. Allergy and Allergic Diseases, 2 Volume Set. 2nd ed. New York: Wiley-Blackwell; 2008. 2184 р.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Akdis CA, Agache I. EAACI Global Atlas of Allergy. Zurich: European Academy of Allergy and Clinical Immunology; 2014.</mixed-citation><mixed-citation xml:lang="ru">Akdis C.A., Agache I. EAACI Global Atlas of Allergy. Zurich: European Academy of Allergy and Clinical Immunology; 2014.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Galli SJ. The mast Cell-IgE paradox: from homeostasis to anaphylaxis. Am J Pathol. 2016;186(2):212–224. doi: 10.1016/j.ajpath.2015.07.025</mixed-citation><mixed-citation xml:lang="ru">Galli S.J. The mast Cell-IgE paradox: from homeostasis to anaphylaxis // Am J Pathol. 2016. Vol. 186, N 2. P. 212–224. doi: 10.1016/j.ajpath.2015.07.025</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Burton OT, Oettgen HC. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol Rev. 2011;242(1):128–143. doi: 10.1111/j.1600-065X.2011.01024.x</mixed-citation><mixed-citation xml:lang="ru">Burton O.T., Oettgen H.C. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases // Immunol Rev. 2011. Vol. 242, N 1. P. 128–143. doi: 10.1111/j.1600-065X.2011.01024.x</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Dudeck A, Köberle M, Goldmann O, et al. Mast cells as protectors of health. J Allergy Clin Immunol. 2019;144(4S):S4–S18. doi: 10.1016/j.jaci.2018.10.054</mixed-citation><mixed-citation xml:lang="ru">Dudeck A., Köberle M., Goldmann O., et al. Mast cells as protectors of health // J Allergy Clin Immunol. 2019. Vol. 144, N 4S. P. S4–S18. doi: 10.1016/j.jaci.2018.10.054</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Mukai K, Tsai M, Starkl P, et al. IgE and mast cells in host defense against parasites and venoms. Semin Immunopathol. 2016;38(5):581–603. doi: 10.1007/s00281-016-0565-1</mixed-citation><mixed-citation xml:lang="ru">Mukai K., Tsai M., Starkl P., et al. IgE and mast cells in host defense against parasites and venoms // Semin Immunopathol. 2016. Vol. 38, N 5. P. 581–603. doi: 10.1007/s00281-016-0565-1</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Yoshikawa S, Miyake K, Kamiya A, Karasuyama H. The role of basophils in acquired protective immunity to tick infestation. Parasite Immunol. 2021;43(5):e12804. doi: 10.1111/pim.12804</mixed-citation><mixed-citation xml:lang="ru">Yoshikawa S., Miyake K., Kamiya A., Karasuyama H. The role of basophils in acquired protective immunity to tick infestation // Parasite Immunol. 2021. Vol. 43, N 5. P. e12804. doi: 10.1111/pim.12804</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241. doi: 10.3390/ijms20174241</mixed-citation><mixed-citation xml:lang="ru">Marshall J.S., Portales-Cervantes L., Leong E. Mast cell responses to viruses and pathogen products // Int J Mol Sci. 2019. Vol. 20, N 17. P. 4241. doi: 10.3390/ijms20174241</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Lu F, Huang S. The roles of mast cells in parasitic protozoan infections. Front Immunol. 2017;8:363. doi: 10.3389/fimmu.2017.00363</mixed-citation><mixed-citation xml:lang="ru">Lu F., Huang S. The roles of mast cells in parasitic protozoan infections // Front Immunol. 2017. Vol. 8. Р. 363. doi: 10.3389/fimmu.2017.00363</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Conti P, Caraffa A, Ronconi G, et al. Recent progress on pathophysiology, inflammation and defense mechanism of mast cells against invading microbes: inhibitory effect of IL-37. Cent Eur J Immunol. 2019;44(4):447–454. doi: 10.5114/ceji.2019.92807</mixed-citation><mixed-citation xml:lang="ru">Conti P., Caraffa A., Ronconi G., et al. Recent progress on pathophysiology, inflammation and defense mechanism of mast cells against invading microbes: inhibitory effect of IL-37 // Cent Eur J Immunol. 2019. Vol. 44, N 4. P. 447–454. doi: 10.5114/ceji.2019.92807</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Simon HU, Yousefi S, Germic N, et al. The cellular functions of eosinophils: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(1):11–23. doi: 10.1159/000504847</mixed-citation><mixed-citation xml:lang="ru">Simon H.U., Yousefi S., Germic N., et al. The cellular functions of eosinophils: collegium internationale allergologicum (CIA) update 2020 // Int Arch Allergy Immunol. 2020. Vol. 181, N 1. P. 11–23. doi: 10.1159/000504847</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15:179–209. doi: 10.1146/annurev-pathmechdis-012419-032756</mixed-citation><mixed-citation xml:lang="ru">Klion A.D., Ackerman S.J., Bochner B.S. Contributions of eosinophils to human health and disease // Annu Rev Pathol. 2020. Vol. 15. P. 179–209. doi: 10.1146/annurev-pathmechdis-012419-032756</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature. 2012;484(7395):465–472. doi: 10.1038/nature11047</mixed-citation><mixed-citation xml:lang="ru">Palm N.W., Rosenstein R.K., Medzhitov R. Allergic host defences // Nature. 2012. Vol. 484, N 7395. P. 465–472. doi: 10.1038/nature11047</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Varricchi G, Rossi FW, Galdiero MR, et al. Physiological roles of mast cells: collegium internationale allergologicum update 2019. Int Arch Allergy Immunol. 2019;179(4):247–261. doi: 10.1159/000500088</mixed-citation><mixed-citation xml:lang="ru">Varricchi G., Rossi F.W., Galdiero M.R., et al. Physiological roles of mast cells: collegium internationale allergologicum update 2019 // Int Arch Allergy Immunol. 2019. Vol. 179, N 4. P. 247–261. doi: 10.1159/000500088</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Chauhan J, McCraw AJ, Nakamura M, et al. IgE Antibodies against Cancer: Efficacy and Safety. Antibodies (Basel). 2020;9(4):55. doi: 10.3390/antib9040055</mixed-citation><mixed-citation xml:lang="ru">Chauhan J., McCraw A.J., Nakamura M., et al. IgE Antibodies against Cancer: Efficacy and Safety // Antibodies (Basel). 2020. Vol. 9, N 4. P. 55. doi: 10.3390/antib9040055</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Pritchard DI, Falcone FH, Mitchell PD. The evolution of IgE-mediated type I hypersensitivity and its immunological value. Allergy. 2021;76(4):1024–1040. doi: 10.1111/all.14570</mixed-citation><mixed-citation xml:lang="ru">Pritchard D.I., Falcone F.H., Mitchell P.D. The evolution of IgE-mediated type I hypersensitivity and its immunological value // Allergy. 2021. Vol. 76, N 4. P. 1024–1040. doi: 10.1111/all.14570</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Duarte J, Deshpande P, Guiyedi V, et al. Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status. Malar J. 2007;6:1. doi: 10.1186/1475-2875-6-1</mixed-citation><mixed-citation xml:lang="ru">Duarte J., Deshpande P., Guiyedi V., et al. Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status // Malar J. 2007. Vol. 6. Р. 1. doi: 10.1186/1475-2875-6-1</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Mossalayi MD, Arock M, Mazier D, et al. The human immune response during cutaneous leishmaniasis: NO problem. Parasitol Today. 1999;15(8):342–345. doi: 10.1016/s0169-4758(99)01477-5</mixed-citation><mixed-citation xml:lang="ru">Mossalayi M.D., Arock M., Mazier D., et al. The human immune response during cutaneous leishmaniasis: NO problem // Parasitol Today. 1999. Vol. 15, N 8. P. 342–345. doi: 10.1016/s0169-4758(99)01477-5</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Wright JE, Werkman M, Dunn JC, Anderson RM. Current epidemiological evidence for predisposition to high or low intensity human helminth infection: a systematic review. Parasit Vectors. 2018;11(1):65. doi: 10.1186/s13071-018-2656-4</mixed-citation><mixed-citation xml:lang="ru">Wright J.E., Werkman M., Dunn J.C., Anderson R.M. Current epidemiological evidence for predisposition to high or low intensity human helminth infection: a systematic review // Parasit Vectors. 2018. Vol. 11, N 1. P. 65. doi: 10.1186/s13071-018-2656-4</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Al Amin AS, Wadhwa R. Helminthiasis. 2021 Jul 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.</mixed-citation><mixed-citation xml:lang="ru">Al Amin A.S., Wadhwa R. Helminthiasis. 2021 Jul 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Capron A, Dessaint JP, Haque A, Capron M. Antibody-dependent cell-mediated cytotoxicity against parasites. Prog Allergy. 1982;31:234–267.</mixed-citation><mixed-citation xml:lang="ru">Capron A., Dessaint J.P., Haque A., Capron M. Antibody-dependent cell-mediated cytotoxicity against parasites // Prog Allergy. 1982. Vol. 31. P. 234–267.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Finkelman FD, Shea-Donohue T, Morris SC, et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev. 2004;201:139–155. doi: 10.1111/j.0105-2896.2004.00192.x</mixed-citation><mixed-citation xml:lang="ru">Finkelman F.D., Shea-Donohue T., Morris S.C., et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites // Immunol Rev. 2004. Vol. 201. Р. 139–155. doi: 10.1111/j.0105-2896.2004.00192.x</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Capron A, Dessaint JP. Effector and regulatory mechanisms in immunity to schistosomes: a heuristic view. Annu Rev Immunol. 1985;3:455–476. doi: 10.1146/annurev.iy.03.040185.002323</mixed-citation><mixed-citation xml:lang="ru">Capron A., Dessaint J.P. Effector and regulatory mechanisms in immunity to schistosomes: a heuristic view // Annu Rev Immunol. 1985. Vol. 3. P. 455–476. doi: 10.1146/annurev.iy.03.040185.002323</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Vignali DA, Bickle QD, Taylor MG. Immunity to Schistosoma mansoni in vivo: contradiction or clarification? Immunol Today. 1989;10(12):410–416. doi: 10.1016/0167-5699(89)90038-8</mixed-citation><mixed-citation xml:lang="ru">Vignali D.A., Bickle Q.D., Taylor M.G. Immunity to Schistosoma mansoni in vivo: contradiction or clarification? // Immunol Today. 1989. Vol. 10, N 12. P. 410–416. doi: 10.1016/0167-5699(89)90038-8</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Capron M, Spiegelberg HL, Prin L, et al. Role of IgE receptors in effector function of human eosinophils. J Immunol. 1984; 132(1):462–468.</mixed-citation><mixed-citation xml:lang="ru">Capron M., Spiegelberg H.L., Prin L., et al. Role of IgE receptors in effector function of human eosinophils // J Immunol. 1984. Vol. 132, N 1. P. 462–468.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Auriault C, Damonneville M, Verwaerde C, et al. Rat IgE directed against schistosomula-released products is cytotoxic for Schistosoma mansoni schistosomula in vitro. Eur J Immunol. 1984; 14(2):132–138. doi: 10.1002/eji.1830140206</mixed-citation><mixed-citation xml:lang="ru">Auriault C., Damonneville M., Verwaerde C., et al. Rat IgE directed against schistosomula-released products is cytotoxic for Schistosoma mansoni schistosomula in vitro // Eur J Immunol. 1984. Vol. 14, N 2. P. 132–138. doi: 10.1002/eji.1830140206</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Hagan P, Blumenthal UJ, Dunn D, et al. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature. 1991;349(6306):243–245. doi: 10.1038/349243a0</mixed-citation><mixed-citation xml:lang="ru">Hagan P., Blumenthal U.J., Dunn D., et al. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium // Nature. 1991. Vol. 349, N 6306. P. 243–245. doi: 10.1038/349243a0</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Rihet P, Demeure CE, Bourgois A, et al. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol. 1991;21(11):2679–2686. doi: 10.1002/eji.1830211106</mixed-citation><mixed-citation xml:lang="ru">Rihet P., Demeure C.E., Bourgois A., et al. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels // Eur J Immunol. 1991. Vol. 21, N 11. P. 2679–2686. doi: 10.1002/eji.1830211106</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Dunne DW, Butterworth AE, Fulford AJ, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol. 1992;22(6):1483–1494. doi: 10.1002/eji.1830220622</mixed-citation><mixed-citation xml:lang="ru">Dunne D.W., Butterworth A.E., Fulford A.J., et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection // Eur J Immunol. 1992. Vol. 22, N 6. P. 1483–1494. doi: 10.1002/eji.1830220622</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Spencer LA, Porte P, Zetoff C, Rajan TV. Mice genetically deficient in immunoglobulin E are more permissive hosts than wild-type mice to a primary, but not secondary, infection with the filarial nematode Brugia malayi. Infect Immun. 2003;71(5):2462–2467. doi: 10.1128/IAI.71.5.2462-2467.2003</mixed-citation><mixed-citation xml:lang="ru">Spencer L.A., Porte P., Zetoff C., Rajan T.V. Mice genetically deficient in immunoglobulin E are more permissive hosts than wild-type mice to a primary, but not secondary, infection with the filarial nematode Brugia malayi // Infect Immun. 2003. Vol. 71, N 5. P. 2462–2467. doi: 10.1128/IAI.71.5.2462-2467.2003</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Gurish MF, Bryce PJ, Tao H, et al. IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis. J Immunol. 2004;172(2):1139–1145. doi: 10.4049/jimmunol.172.2.1139</mixed-citation><mixed-citation xml:lang="ru">Gurish M.F., Bryce P.J., Tao H., et al. IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis // J Immunol. 2004. Vol. 172, N 2. P. 1139–1145. doi: 10.4049/jimmunol.172.2.1139</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Schwartz C, Turqueti-Neves A, Hartmann S, et al. Basophil-mediated protection against gastrointestinal helminths requires IgE-induced cytokine secretion. Proc Natl Acad Sci USA. 2014; 111(48):E5169–5177. doi: 10.1073/pnas.1412663111</mixed-citation><mixed-citation xml:lang="ru">Schwartz C., Turqueti-Neves A., Hartmann S., et al. Basophil-mediated protection against gastrointestinal helminths requires IgE-induced cytokine secretion // Proc Natl Acad Sci U S A. 2014. Vol. 111, N 48. P. E5169–5177. doi: 10.1073/pnas.1412663111</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197–207. doi: 10.1111/j.1365-2222.2007.02650.x</mixed-citation><mixed-citation xml:lang="ru">Cruz A.A., Lima F., Sarinho E., et al. Safety of anti- immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection // Clin Exp Allergy. 2007. Vol. 37, N 2. P. 197–207. doi: 10.1111/j.1365-2222.2007.02650.x</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192. doi: 10.1177/1753466618810192</mixed-citation><mixed-citation xml:lang="ru">Pelaia C., Calabrese C., Terracciano R., et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness // Ther Adv Respir Dis. 2018. Vol. 12. P. 1753466618810192. doi: 10.1177/1753466618810192</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Matsumoto M, Sasaki Y, Yasuda K, et al. IgG and IgE collaboratively accelerate expulsion of Strongyloides venezuelensis in a primary infection. Infect Immun. 2013;81(7):2518–2527. doi: 10.1128/IAI.00285-13</mixed-citation><mixed-citation xml:lang="ru">Matsumoto M., Sasaki Y., Yasuda K., et al. IgG and IgE collaboratively accelerate expulsion of Strongyloides venezuelensis in a primary infection // Infect Immun. 2013. Vol. 81, N 7. P. 2518–2527. doi: 10.1128/IAI.00285-13</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Watanabe N, Katakura K, Kobayashi A, et al. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis // Proc Natl Acad Sci USA. 1988;85(12):4460–4462. doi: 10.1073/pnas.85.12.4460</mixed-citation><mixed-citation xml:lang="ru">Watanabe N., Katakura K., Kobayashi A., et al. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis // Proc Natl Acad Sci U S A. 1988. Vol. 85, N 12. P. 4460–4462. doi: 10.1073/pnas.85.12.4460</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Watanabe N. Impaired protection against Trichinella spiralis in mice with high levels of IgE. Parasitol Int. 2014;63(2):332–336. doi: 10.1016/j.parint.2013.12.004</mixed-citation><mixed-citation xml:lang="ru">Watanabe N. Impaired protection against Trichinella spiralis in mice with high levels of IgE // Parasitol Int. 2014. Vol. 63, N 2. P. 332–336. doi: 10.1016/j.parint.2013.12.004</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Pritchard DI. Immunity to helminths: is too much IgE parasite--rather than host-protective? Parasite Immunol. 1993;15(1):5–9. doi: 10.1111/j.1365-3024.1993.tb00566.x</mixed-citation><mixed-citation xml:lang="ru">Pritchard D.I. Immunity to helminths: is too much IgE parasite--rather than host-protective? // Parasite Immunol. 1993. Vol. 15, N 1. P. 5–9. doi: 10.1111/j.1365-3024.1993.tb00566.x</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Pritchard DI, Hewitt C, Moqbel R. The relationship between immunological responsiveness controlled by T-helper 2 lymphocytes and infections with parasitic helminths. Parasitology. 1997;115(Suppl):S33–44. doi: 10.1017/s0031182097001996</mixed-citation><mixed-citation xml:lang="ru">Pritchard D.I., Hewitt C., Moqbel R. The relationship between immunological responsiveness controlled by T-helper 2 lymphocytes and infections with parasitic helminths // Parasitology. 1997. Vol. 115, Suppl. C. S33–44. doi: 10.1017/s0031182097001996</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Amiri P, Haak-Frendscho M, Robbins K, et al. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med. 1994;180(1):43–51. doi: 10.1084/jem.180.1.43</mixed-citation><mixed-citation xml:lang="ru">Amiri P., Haak-Frendscho M., Robbins K., et al. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice // J Exp Med. 1994. Vol. 180, N 1. P. 43–51. doi: 10.1084/jem.180.1.43</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">King CL, Xianli J, Malhotra I, et al. Mice with a targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with Schistosoma mansoni. J Immunol. 1997;158(1):294–300.</mixed-citation><mixed-citation xml:lang="ru">King C.L., Xianli J., Malhotra I., et al. Mice with a targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with Schistosoma mansoni // J Immunol. 1997. Vol. 158, N 1. P. 294–300.</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Jankovic D, Kullberg MC, Dombrowicz D, et al. Fc epsilonRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology. J Immunol. 1997;159(4):1868–1875.</mixed-citation><mixed-citation xml:lang="ru">Jankovic D., Kullberg M.C., Dombrowicz D., et al. Fc epsilonRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology // J Immunol. 1997. Vol. 159, N 4. P. 1868–1875.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Martin RK, Damle SR, Valentine YA, et al. B1 Cell IgE impedes mast cell-mediated enhancement of parasite expulsion through B2 IgE blockade. Cell Rep. 2018;22(7):1824–1834. doi: 10.1016/j.celrep.2018.01.048</mixed-citation><mixed-citation xml:lang="ru">Martin R.K., Damle S.R., Valentine Y.A., et al. B1 Cell IgE impedes mast cell-mediated enhancement of parasite expulsion through B2 IgE blockade // Cell Rep. 2018. Vol. 22, N 7. P. 1824–1834. doi: 10.1016/j.celrep.2018.01.048</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J Exp Med. 2011;208(1):67–80. doi: 10.1084/jem.20101499</mixed-citation><mixed-citation xml:lang="ru">Griffin D.O., Holodick N.E., Rothstein T.L. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70- // J Exp Med. 2011. Vol. 208, N 1. P. 67–80. doi: 10.1084/jem.20101499</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Pennock JL, Grencis RK. The mast cell and gut nematodes: damage and defence. Chem Immunol Allergy. 2006;90:128–140. doi: 10.1159/000088885</mixed-citation><mixed-citation xml:lang="ru">Pennock J.L., Grencis R.K. The mast cell and gut nematodes: damage and defence // Chem Immunol Allergy. 2006. Vol. 90. P. 128–140. doi: 10.1159/000088885.</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Abe T, Sugaya H, Ishida K, et al. Intestinal protection against Strongyloides ratti and mastocytosis induced by administration of interleukin-3 in mice. Immunology. 1993;80(1):116–21.</mixed-citation><mixed-citation xml:lang="ru">Abe T., Sugaya H., Ishida K., et al. Intestinal protection against Strongyloides ratti and mastocytosis induced by administration of interleukin-3 in mice // Immunology. 1993. Vol. 80, N 1. P. 116–121.</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><citation-alternatives><mixed-citation xml:lang="en">Sasaki Y, Yoshimoto T, Maruyama H, et al. IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity. J Exp Med. 2005;202(5):607–616. doi: 10.1084/jem.20042202</mixed-citation><mixed-citation xml:lang="ru">Sasaki Y., Yoshimoto T., Maruyama H., et al. IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity // J Exp Med. 2005. Vol. 202, N 5. P. 607–616. doi: 10.1084/jem.20042202</mixed-citation></citation-alternatives></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">Grencis RK, Else KJ, Huntley JF, Nishikawa SI. The in vivo role of stem cell factor (c-kit ligand) on mastocytosis and host protective immunity to the intestinal nematode Trichinella spiralis in mice. Parasite Immunol. 1993;15(1):55–59. doi: 10.1111/j.1365-3024.1993.tb00572.x</mixed-citation><mixed-citation xml:lang="ru">Grencis R.K., Else K.J., Huntley J.F., Nishikawa S.I. The in vivo role of stem cell factor (c-kit ligand) on mastocytosis and host protective immunity to the intestinal nematode Trichinella spiralis in mice // Parasite Immunol. 1993. Vol. 15, N 1. P. 55–59. doi: 10.1111/j.1365-3024.1993.tb00572.x</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">Donaldson LE, Schmitt E, Huntley JF, et al. A critical role for stem cell factor and c-kit in host protective immunity to an intestinal helminth. Int Immunol. 1996;8(4):559–567. doi: 10.1093/intimm/8.4.559</mixed-citation><mixed-citation xml:lang="ru">Donaldson L.E., Schmitt E., Huntley J.F., et al. A critical role for stem cell factor and c-kit in host protective immunity to an intestinal helminth // Int Immunol. 1996. Vol. 8, N 4. P. 559–67. doi: 10.1093/intimm/8.4.559</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">Lantz CS, Boesiger J, Song CH, et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. 1998;392(6671):90–93. doi: 10.1038/32190</mixed-citation><mixed-citation xml:lang="ru">Lantz C.S., Boesiger J., Song C.H., et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature // 1998. Vol. 392, N 6671. P. 90–93. doi: 10.1038/32190</mixed-citation></citation-alternatives></ref><ref id="B63"><label>63.</label><citation-alternatives><mixed-citation xml:lang="en">Koyama K, Ito Y. Mucosal mast cell responses are not required for protection against infection with the murine nematode parasite Trichuris muris. Parasite Immunol. 2000;22(1):13–20. doi: 10.1046/j.1365-3024.2000.00270.x</mixed-citation><mixed-citation xml:lang="ru">Koyama K., Ito Y. Mucosal mast cell responses are not required for protection against infection with the murine nematode parasite Trichuris muris // Parasite Immunol. 2000. Vol. 22, N 1. P. 13–20. doi: 10.1046/j.1365-3024.2000.00270.x</mixed-citation></citation-alternatives></ref><ref id="B64"><label>64.</label><citation-alternatives><mixed-citation xml:lang="en">Knight PA, Wright SH, Lawrence CE, et al. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med. 2000;192(12):1849–1856. doi: 10.1084/jem.192.12.1849</mixed-citation><mixed-citation xml:lang="ru">Knight P.A., Wright S.H., Lawrence C.E., et al. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1 // J Exp Med. 2000. Vol. 192, N 12. P. 1849–1856. doi: 10.1084/jem.192.12.1849</mixed-citation></citation-alternatives></ref><ref id="B65"><label>65.</label><citation-alternatives><mixed-citation xml:lang="en">McKean PG, Pritchard DI. The action of a mast cell protease on the cuticular collagens of Necator americanus. Parasite Immunol. 1989;11(3):293–297. doi: 10.1111/j.1365-3024.1989.tb00667.x</mixed-citation><mixed-citation xml:lang="ru">McKean P.G., Pritchard D.I. The action of a mast cell protease on the cuticular collagens of Necator americanus // Parasite Immunol. 1989. Vol. 11, N 3. P. 293–297. doi: 10.1111/j.1365-3024.1989.tb00667.x</mixed-citation></citation-alternatives></ref><ref id="B66"><label>66.</label><citation-alternatives><mixed-citation xml:lang="en">Marzio L, Blennerhassett P, Vermillion D, et al. Distribution of mast cells in intestinal muscle of nematode-sensitized rats. Am J Physiol. 1992;262(3 Pt 1):G477–482. doi: 10.1152/ajpgi.1992.262.3.G477</mixed-citation><mixed-citation xml:lang="ru">Marzio L., Blennerhassett P., Vermillion D., et al. Distribution of mast cells in intestinal muscle of nematode-sensitized rats // Am J Physiol. 1992. Vol. 262, N 3, Pt 1. P. G477–482. doi: 10.1152/ajpgi.1992.262.3.G477</mixed-citation></citation-alternatives></ref><ref id="B67"><label>67.</label><citation-alternatives><mixed-citation xml:lang="en">Madden KB, Whitman L, Sullivan C, et al. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol. 2002;169(8):4417–4422. doi: 10.4049/jimmunol.169.8.4417</mixed-citation><mixed-citation xml:lang="ru">Madden K.B., Whitman L., Sullivan C., et al. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function // J Immunol. 2002. Vol. 169, N 8. P. 4417–4422. doi: 10.4049/jimmunol.169.8.4417</mixed-citation></citation-alternatives></ref><ref id="B68"><label>68.</label><citation-alternatives><mixed-citation xml:lang="en">McDermott JR, Bartram RE, Knight PA, et al. Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl Acad Sci USA. 2003;100(13):7761–7766. doi: 10.1073/pnas.1231488100</mixed-citation><mixed-citation xml:lang="ru">McDermott J.R., Bartram R.E., Knight P.A., et al. Mast cells disrupt epithelial barrier function during enteric nematode infection // Proc Natl Acad Sci USA. 2003. Vol. 100, N 13. P. 7761–7766. doi: 10.1073/pnas.1231488100</mixed-citation></citation-alternatives></ref><ref id="B69"><label>69.</label><citation-alternatives><mixed-citation xml:lang="en">Maruyama H, Yabu Y, Yoshida A, et al. A role of mast cell glycosaminoglycans for the immunological expulsion of intestinal nematode, Strongyloides venezuelensis. J Immunol. 2000;164(7): 3749–3754. doi: 10.4049/jimmunol.164.7.3749</mixed-citation><mixed-citation xml:lang="ru">Maruyama H., Yabu Y., Yoshida A., et al. A role of mast cell glycosaminoglycans for the immunological expulsion of intestinal nematode, Strongyloides venezuelensis // J Immunol. 2000. Vol. 164, N 7. P. 3749–3754. doi: 10.4049/jimmunol.164.7.3749</mixed-citation></citation-alternatives></ref><ref id="B70"><label>70.</label><citation-alternatives><mixed-citation xml:lang="en">Ohnmacht C, Voehringer D. Basophils protect against reinfection with hookworms independently of mast cells and memory Th2 cells. J Immunol. 2010;184(1):344–350. doi: 10.4049/jimmunol.0901841</mixed-citation><mixed-citation xml:lang="ru">Ohnmacht C., Voehringer D. Basophils protect against reinfection with hookworms independently of mast cells and memory Th2 cells // J Immunol. 2010. Vol. 184, N 1. P. 344–350. doi: 10.4049/jimmunol.0901841</mixed-citation></citation-alternatives></ref><ref id="B71"><label>71.</label><citation-alternatives><mixed-citation xml:lang="en">Ohnmacht C, Schwartz C, Panzer M, et al. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity. 2010;33(3):364–374. doi: 10.1016/j.immuni.2010.08.011</mixed-citation><mixed-citation xml:lang="ru">Ohnmacht C., Schwartz C., Panzer M., et al. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths // Immunity. 2010. Vol. 33, N 3. P. 364–374. doi: 10.1016/j.immuni.2010.08.011</mixed-citation></citation-alternatives></ref><ref id="B72"><label>72.</label><citation-alternatives><mixed-citation xml:lang="en">Sullivan BM, Liang HE, Bando JK, et al. Genetic analysis of basophil function in vivo. Nat Immunol. 2011;12(6):527–535. doi: 10.1038/ni.2036</mixed-citation><mixed-citation xml:lang="ru">Sullivan B.M., Liang H.E., Bando J.K., et al. Genetic analysis of basophil function in vivo // Nat Immunol. 2011. Vol. 12, N 6. P. 527–535. doi: 10.1038/ni.2036</mixed-citation></citation-alternatives></ref><ref id="B73"><label>73.</label><citation-alternatives><mixed-citation xml:lang="en">Linnemann LC, Reitz M, Feyerabend TB, et al. Limited role of mast cells during infection with the parasitic nematode Litomosoides sigmodontis. PLoS Negl Trop Dis. 2020;14(7):e0008534. doi: 10.1371/journal.pntd.0008534</mixed-citation><mixed-citation xml:lang="ru">Linnemann L.C., Reitz M., Feyerabend T.B., et al. Limited role of mast cells during infection with the parasitic nematode Litomosoides sigmodontis // PLoS Negl Trop Dis. 2020. Vol. 14, N 7. P. e0008534. doi: 10.1371/journal.pntd.0008534</mixed-citation></citation-alternatives></ref><ref id="B74"><label>74.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS. Interactions of mast cells and eosinophils in allergic response. Russ J Allergy. 2020;17(2):5–17. (In Russ). doi: 10.36691/RJA1363</mixed-citation><mixed-citation xml:lang="ru">Гущин ИС. Взаимодействие тучных клеток и эозинофилов в аллергическом ответе // Российский Аллергологический Журнал. 2020. Т. 17, № 2. С. 5–17. doi: 10.36691/RJA1363</mixed-citation></citation-alternatives></ref><ref id="B75"><label>75.</label><citation-alternatives><mixed-citation xml:lang="en">Behm CA, Ovington KS. The role of eosinophils in parasitic helminth infections: insights from genetically modified mice. Parasitol Today. 2000;16(5):202–209. doi: 10.1016/s0169-4758(99)01620-8</mixed-citation><mixed-citation xml:lang="ru">Behm C.A., Ovington K.S. The role of eosinophils in parasitic helminth infections: insights from genetically modified mice // Parasitol Today. 2000. Vol. 16, N 5. P. 202–209. doi: 10.1016/s0169-4758(99)01620-8</mixed-citation></citation-alternatives></ref><ref id="B76"><label>76.</label><citation-alternatives><mixed-citation xml:lang="en">Butterworth AE. Cell-mediated damage to helminths. Adv Parasitol. 1984;23:143–235. doi: 10.1016/s0065-308x(08)60287-0</mixed-citation><mixed-citation xml:lang="ru">Butterworth A.E. Cell-mediated damage to helminths // Adv Parasitol. 1984. Vol. 23. P. 143–235. doi: 10.1016/s0065-308x(08)60287-0</mixed-citation></citation-alternatives></ref><ref id="B77"><label>77.</label><citation-alternatives><mixed-citation xml:lang="en">Hagan P, Wilkins HA, Blumenthal UJ, et al. Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunol. 1985;7(6):625–632. doi: 10.1111/j.1365-3024.1985.tb00106.x</mixed-citation><mixed-citation xml:lang="ru">Hagan P., Wilkins H.A., Blumenthal U.J., et al. Eosinophilia and resistance to Schistosoma haematobium in man // Parasite Immunol. 1985. Vol. 7, N 6. P. 625–632. doi: 10.1111/j.1365-3024.1985.tb00106.x</mixed-citation></citation-alternatives></ref><ref id="B78"><label>78.</label><citation-alternatives><mixed-citation xml:lang="en">Sturrock RF, Kimani R, Cottrell BJ, et al. Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1983;77(3):363–371. doi: 10.1016/0035-9203(83)90166-9</mixed-citation><mixed-citation xml:lang="ru">Sturrock R.F., Kimani R., Cottrell B.J., et al. Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni // Trans R Soc Trop Med Hyg. 1983. Vol. 77, N 3. P. 363–371. doi: 10.1016/0035-9203(83)90166-9</mixed-citation></citation-alternatives></ref><ref id="B79"><label>79.</label><citation-alternatives><mixed-citation xml:lang="en">Butterworth AE. The eosinophil and its role in immunity to helminth infection. Curr Top Microbiol Immunol. 1977;77:127–168. doi: 10.1007/978-3-642-66740-4_5</mixed-citation><mixed-citation xml:lang="ru">Butterworth A.E. The eosinophil and its role in immunity to helminth infection // Curr Top Microbiol Immunol. 1977. Vol. 77. Р. 127–168. doi: 10.1007/978-3-642-66740-4_5</mixed-citation></citation-alternatives></ref><ref id="B80"><label>80.</label><citation-alternatives><mixed-citation xml:lang="en">Motran CC, Silvane L, Chiapello LS, et al. Helminth infections: recognition and modulation of the immune response by innate immune cells. Front Immunol. 2018;9:664. doi: 10.3389/fimmu.2018.00664</mixed-citation><mixed-citation xml:lang="ru">Motran C.C., Silvane L., Chiapello L.S., et al. Helminth infections: recognition and modulation of the immune response by innate immune cells // Front Immunol. 2018. Vol. 9. P. 664. doi: 10.3389/fimmu.2018.00664</mixed-citation></citation-alternatives></ref><ref id="B81"><label>81.</label><citation-alternatives><mixed-citation xml:lang="en">Sasaki O, Sugaya H, Ishida K, Yoshimura K. Ablation of eosinophils with anti-IL-5 antibody enhances the survival of intracranial worms of Angiostrongylus cantonensis in the mouse. Parasite Immunol. 1993;15(6):349–354. doi: 10.1111/j.1365-3024.1993.tb00619.x</mixed-citation><mixed-citation xml:lang="ru">Sasaki O., Sugaya H., Ishida K., Yoshimura K. Ablation of eosinophils with anti-IL-5 antibody enhances the survival of intracranial worms of Angiostrongylus cantonensis in the mouse // Parasite Immunol. 1993. Vol. 15, N 6. P. 349–354. doi: 10.1111/j.1365-3024.1993.tb00619.x</mixed-citation></citation-alternatives></ref><ref id="B82"><label>82.</label><citation-alternatives><mixed-citation xml:lang="en">Ehrens A, Rüdiger N, Heepmann L, et al. Eosinophils and neutrophils eliminate migrating strongyloides ratti larvae at the site of infection in the context of extracellular DNA trap formation. Front Immunol. 2021;12:715766. doi: 10.3389/fimmu.2021.715766</mixed-citation><mixed-citation xml:lang="ru">Ehrens A., Rüdiger N., Heepmann L., et al. Eosinophils and neutrophils eliminate migrating strongyloides ratti larvae at the site of infection in the context of extracellular DNA trap formation // Front Immunol. 2021. Vol. 12. P. 715766. doi: 10.3389/fimmu.2021.715766</mixed-citation></citation-alternatives></ref><ref id="B83"><label>83.</label><citation-alternatives><mixed-citation xml:lang="en">Turner JD, Pionnier N, Furlong-Silva J, et al. Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia // PLoS Pathog. 2018;14(3):e1006949. doi: 10.1371/journal.ppat.1006949</mixed-citation><mixed-citation xml:lang="ru">Turner J.D., Pionnier N., Furlong-Silva J., et al. Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia // PLoS Pathog. 2018. Vol. 14, N 3. P. e1006949. doi: 10.1371/journal.ppat.1006949</mixed-citation></citation-alternatives></ref><ref id="B84"><label>84.</label><citation-alternatives><mixed-citation xml:lang="en">Frohberger SJ, Ajendra J, Surendar J, et al. Susceptibility to L. sigmodontis infection is highest in animals lacking IL-4R/IL-5 compared to single knockouts of IL-4R, IL-5 or eosinophils. Parasit Vectors. 2019;12(1):248. doi: 10.1186/s13071-019-3502-z</mixed-citation><mixed-citation xml:lang="ru">Frohberger S.J., Ajendra J., Surendar J., et al. Susceptibility to L. sigmodontis infection is highest in animals lacking IL-4R/IL-5 compared to single knockouts of IL-4R, IL-5 or eosinophils // Parasit Vectors. 2019. Vol. 12, N 1. P. 248. doi: 10.1186/s13071-019-3502-z</mixed-citation></citation-alternatives></ref><ref id="B85"><label>85.</label><citation-alternatives><mixed-citation xml:lang="en">Eriksson J, Reimert CM, Kabatereine NB, et al. The 434(G&gt;C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol. 2007;37(12):1359–1366. doi: 10.1016/j.ijpara.2007.04.001</mixed-citation><mixed-citation xml:lang="ru">Eriksson J., Reimert C.M., Kabatereine N.B., et al. The 434(G&gt;C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection // Int J Parasitol. 2007. Vol. 37, N 12. P. 1359–1366. doi: 10.1016/j.ijpara.2007.04.001</mixed-citation></citation-alternatives></ref><ref id="B86"><label>86.</label><citation-alternatives><mixed-citation xml:lang="en">Swartz JM, Dyer KD, Cheever AW, et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood. 2006;108(7): 2420–2427. doi: 10.1182/blood-2006-04-015933</mixed-citation><mixed-citation xml:lang="ru">Swartz J.M., Dyer K.D., Cheever A.W., et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice // Blood. 2006. Vol. 108, N 7. P. 2420–2427. doi: 10.1182/blood-2006-04-015933</mixed-citation></citation-alternatives></ref><ref id="B87"><label>87.</label><citation-alternatives><mixed-citation xml:lang="en">Sher A, Coffman RL, Hieny S, Cheever AW. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol. 1990;145(11):3911–3916.</mixed-citation><mixed-citation xml:lang="ru">Sher A., Coffman R.L., Hieny S., Cheever A.W. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse // J Immunol. 1990. Vol. 145, N 11. P. 3911–3916.</mixed-citation></citation-alternatives></ref><ref id="B88"><label>88.</label><citation-alternatives><mixed-citation xml:lang="en">Fabre V, Beiting DP, Bliss SK, et al. Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol. 2009;182(3):1577–1583. doi: 10.4049/jimmunol.182.3.1577</mixed-citation><mixed-citation xml:lang="ru">Fabre V., Beiting D.P., Bliss S.K., et al. Eosinophil deficiency compromises parasite survival in chronic nematode infection // J Immunol. 2009. Vol. 182, N 3. P. 1577–1583. doi: 10.4049/jimmunol.182.3.1577</mixed-citation></citation-alternatives></ref><ref id="B89"><label>89.</label><citation-alternatives><mixed-citation xml:lang="en">Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113(1): 30–37. doi: 10.1016/j.jaci.2003.10.050</mixed-citation><mixed-citation xml:lang="ru">Klion A.D., Nutman T.B. The role of eosinophils in host defense against helminth parasites // J Allergy Clin Immunol. 2004. Vol. 113, N 1. P. 30–37. doi: 10.1016/j.jaci.2003.10.050</mixed-citation></citation-alternatives></ref><ref id="B90"><label>90.</label><citation-alternatives><mixed-citation xml:lang="en">Kanda A, Yasutaka Y, Van Bui D, et al. Multiple biological aspects of eosinophils in host defense, eosinophil-associated diseases, immunoregulation, and homeostasis: is their role beneficial, detrimental, regulator, or bystander? Biol Pharm Bull. 2020;43(1): 20–30. doi: 10.1248/bpb.b19-00892</mixed-citation><mixed-citation xml:lang="ru">Kanda A., Yasutaka Y., Van Bui D., et al. Multiple biological aspects of eosinophils in host defense, eosinophil-associated diseases, immunoregulation, and homeostasis: is their role beneficial, detrimental, regulator, or bystander? // Biol Pharm Bull. 2020. Vol. 43, N 1. P. 20–30. doi: 10.1248/bpb.b19-00892</mixed-citation></citation-alternatives></ref><ref id="B91"><label>91.</label><citation-alternatives><mixed-citation xml:lang="en">Mpairwe H, Amoah AS. Parasites and allergy: Observations from Africa. Parasite Immunol. 2019;41(6):e12589. doi: 10.1111/pim.12589</mixed-citation><mixed-citation xml:lang="ru">Mpairwe H., Amoah A.S. Parasites and allergy: Observations from Africa // Parasite Immunol. 2019. Vol. 41, N 6. P. e12589. doi: 10.1111/pim.12589</mixed-citation></citation-alternatives></ref><ref id="B92"><label>92.</label><citation-alternatives><mixed-citation xml:lang="en">Fitzsimmons CM, Falcone FH, Dunne DW. Helminth allergens, parasite-specific IgE, and its protective role in human immunity. Front Immunol. 2014;5:61. doi: 10.3389/fimmu.2014.00061</mixed-citation><mixed-citation xml:lang="ru">Fitzsimmons C.M., Falcone F.H., Dunne D.W. Helminth allergens, parasite-specific IgE, and its protective role in human immunity // Front Immunol. 2014. Vol. 5. P. 61. doi: 10.3389/fimmu.2014.00061</mixed-citation></citation-alternatives></ref><ref id="B93"><label>93.</label><citation-alternatives><mixed-citation xml:lang="en">Grencis RK, Humphreys NE, Bancroft AJ. Immunity to gastrointestinal nematodes: mechanisms and myths. Immunol Rev. 2014;260(1):183–205. doi: 10.1111/imr.12188</mixed-citation><mixed-citation xml:lang="ru">Grencis R.K., Humphreys N.E., Bancroft A.J. Immunity to gastrointestinal nematodes: mechanisms and myths // Immunol Rev. 2014. Vol. 260, N 1. P. 183–205. doi: 10.1111/imr.12188</mixed-citation></citation-alternatives></ref><ref id="B94"><label>94.</label><citation-alternatives><mixed-citation xml:lang="en">Anthony RM, Rutitzky LI, Urban JF et al. Protective immune mechanisms in helminth infection. Nat Rev Immunol. 2007;7(12): 975–979. doi: 10.1038/nri2199</mixed-citation><mixed-citation xml:lang="ru">Anthony R.M., Rutitzky L.I., Urban J.F., et al. Protective immune mechanisms in helminth infection // Nat Rev Immunol. 2007. Vol. 7, N 12. P. 975–987. doi: 10.1038/nri2199</mixed-citation></citation-alternatives></ref><ref id="B95"><label>95.</label><citation-alternatives><mixed-citation xml:lang="en">Zelya OP, Kukina IV. Human babesiosis. Med News North Caucasus. 2020;15(3):449–455. (In Russ). doi: 10.14300/mnnc.2020.15107</mixed-citation><mixed-citation xml:lang="ru">Зеля О.П., Кукина И.В. Бабезиоз человека // Медицинский вестник Северного Кавказа. 2020. Т. 15, № 3. С. 449–455. doi: 10.14300/mnnc.2020.15107</mixed-citation></citation-alternatives></ref><ref id="B96"><label>96.</label><citation-alternatives><mixed-citation xml:lang="en">Sizikova TE, Lebedev VN, Pantukhov VB, Borisevich SV. Severe fever with thrombocytopenia syndrome: the disease, caused by the novel phlebovirus. Problems Virol. 2017;62(2):60–65. (In Russ). doi: 10.18821/0507-4088-2017-62-2-60-65</mixed-citation><mixed-citation xml:lang="ru">Сизикова Т.Е., Лебедев В.Н., Пантюхов В.Б., Борисевич С.В. Острая лихорадка с тромбоцитопеническим синдромом: заболевание, вызываемое новым флебовирусом // Вопросы вирусологии. 2017. Т. 62, № 2. С. 60–65. doi: 10.18821/0507-4088-2017-62-2-60-65</mixed-citation></citation-alternatives></ref><ref id="B97"><label>97.</label><citation-alternatives><mixed-citation xml:lang="en">Yankovskaya YD, Chernobrovkinya TY, Onuhova MP, et al. Some epidemiological aspects associated with infections transmitted by ixodid ticks in metropolitan city. Archive Int Med. 2017;7(6):423–432. (In Russ). doi: 10.20514/2226-6704-2017-7-6-423-432</mixed-citation><mixed-citation xml:lang="ru">Янковская Я.Д., Чернобровкина Т.Я., Онухова М.П., и др. Некоторые эпидемиологические аспекты инфекций, передающихся иксодовыми клещами, на территории мегаполиса // Архивъ внутренней медицины. 2017. Т. 7, № 6. С. 423–432. doi: 10.20514/2226-6704-2017-7-6-423-432</mixed-citation></citation-alternatives></ref><ref id="B98"><label>98.</label><citation-alternatives><mixed-citation xml:lang="en">Keshavarz B, Erickson LD, Platts-Mills TA, Wilson JM. Lessons in innate and allergic immunity from dust mite feces and tick bites front. Allergy. 2021;2:692643. doi: 10.3389/falgy.2021</mixed-citation><mixed-citation xml:lang="ru">Keshavarz B., Erickson L.D., Platts-Mills T.A., Wilson J.M. Lessons in innate and allergic immunity from dust mite feces and tick bites // Front Allergy. 2021. Vol. 2. P. 692643. doi: 10.3389/falgy.2021</mixed-citation></citation-alternatives></ref><ref id="B99"><label>99.</label><citation-alternatives><mixed-citation xml:lang="en">Commins SP. Diagnosis &amp; management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clin Immunol. 2020; 16(7):667–677. doi: 10.1080/1744666X.2020.1782745</mixed-citation><mixed-citation xml:lang="ru">Commins S.P. Diagnosis &amp; management of alpha-gal syndrome: lessons from 2,500 patients // Expert Rev Clin Immunol. 2020. Vol. 16, N 7. P. 667–677. doi: 10.1080/1744666X.2020.1782745</mixed-citation></citation-alternatives></ref><ref id="B100"><label>100.</label><citation-alternatives><mixed-citation xml:lang="en">Trager W. Acquired immunity to ticks. J Parasitol. 1939; 25(1):57–81.</mixed-citation><mixed-citation xml:lang="ru">Trager W. Acquired immunity to ticks // J Parasitol. 1939. Vol. 25, N 1. P. 57–81.</mixed-citation></citation-alternatives></ref><ref id="B101"><label>101.</label><citation-alternatives><mixed-citation xml:lang="en">Wikel SK. Host immunity to ticks. Annu Rev Entomol. 1996; 41:1–22. doi: 10.1146/annurev.en.41.010196.000245</mixed-citation><mixed-citation xml:lang="ru">Wikel S.K. Host immunity to ticks // Annu Rev Entomol. 1996. Vol. 41. P. 1–22. doi: 10.1146/annurev.en.41.010196.000245</mixed-citation></citation-alternatives></ref><ref id="B102"><label>102.</label><citation-alternatives><mixed-citation xml:lang="en">Allen JR. Immunology of interactions between ticks and laboratory animals. Exp Appl Acarol. 1989;7(1):5–13. doi: 10.1007/BF01200448</mixed-citation><mixed-citation xml:lang="ru">Allen J.R. Immunology of interactions between ticks and laboratory animals // Exp Appl Acarol. 1989. Vol. 7, N 1. P. 5–13. doi: 10.1007/BF01200448</mixed-citation></citation-alternatives></ref><ref id="B103"><label>103.</label><citation-alternatives><mixed-citation xml:lang="en">Wikel SK. Tick modulation of host immunity: an important factor in pathogen transmission. Int J Parasitol. 1999;29(6):851–859. doi: 10.1016/s0020-7519(99)00042-9</mixed-citation><mixed-citation xml:lang="ru">Wikel S.K. Tick modulation of host immunity: an important factor in pathogen transmission // Int J Parasitol. 1999. Vol. 29, N 6. P. 851–859. doi: 10.1016/s0020-7519(99)00042-9</mixed-citation></citation-alternatives></ref><ref id="B104"><label>104.</label><citation-alternatives><mixed-citation xml:lang="en">Kazimírová M, Štibrániová I. Tick salivary compounds: their role in modulation of host defences and pathogen transmission. Front Cell Infect Microbiol. 2013;3:43. doi: 10.3389/fcimb.2013.00043</mixed-citation><mixed-citation xml:lang="ru">Kazimírová M., Štibrániová I. Tick salivary compounds: their role in modulation of host defences and pathogen transmission // Front Cell Infect Microbiol. 2013. Vol. 3. P. 43. doi: 10.3389/fcimb.2013.00043</mixed-citation></citation-alternatives></ref><ref id="B105"><label>105.</label><citation-alternatives><mixed-citation xml:lang="en">Burke G, Wikel SK, Spielman A, et al.; Tick-borne Infection Study Group. Hypersensitivity to ticks and Lyme disease risk. Emerg Infect Dis. 2005;11(1):36–41. doi: 10.3201/eid1101.040303</mixed-citation><mixed-citation xml:lang="ru">Burke G., Wikel S.K., Spielman A., et al.; Tick-borne Infection Study Group. Hypersensitivity to ticks and Lyme disease risk // Emerg Infect Dis. 2005. Vol. 11, N 1. P. 36–41. doi: 10.3201/eid1101.040303</mixed-citation></citation-alternatives></ref><ref id="B106"><label>106.</label><citation-alternatives><mixed-citation xml:lang="en">Wikel SK, Allen JR. Acquired resistance to ticks. I. Passive transfer of resistance. Immunology. 1976;30(3):311–316.</mixed-citation><mixed-citation xml:lang="ru">Wikel S.K., Allen J.R. Acquired resistance to ticks. I. Passive transfer of resistance // Immunology. 1976. Vol. 30, N 3. P. 311–316.</mixed-citation></citation-alternatives></ref><ref id="B107"><label>107.</label><citation-alternatives><mixed-citation xml:lang="en">Brown SJ, Askenase PW. Amblyomma americanum: requirement for host Fc receptors in antibody-mediated acquired immune resistance to ticks. Exp Parasitol. 1985;59(2):248–256. doi: 10.1016/0014-4894(85)90079-7</mixed-citation><mixed-citation xml:lang="ru">Brown S.J., Askenase P.W. Amblyomma americanum: requirement for host Fc receptors in antibody-mediated acquired immune resistance to ticks // Exp Parasitol. 1985. Vol. 59, N 2. P. 248–256. doi: 10.1016/0014-4894(85)90079-7</mixed-citation></citation-alternatives></ref><ref id="B108"><label>108.</label><citation-alternatives><mixed-citation xml:lang="en">Askenase PW, Bagnall BG, Worms MJ. Cutaneous basophil-associated resistance to ectoparasites (ticks). I. Transfer with immune serum or immune cells. Immunology. 1982;45(3):501–511.</mixed-citation><mixed-citation xml:lang="ru">Askenase P.W., Bagnall B.G., Worms M.J. Cutaneous basophil-associated resistance to ectoparasites (ticks). I. Transfer with immune serum or immune cells // Immunology. 1982. Vol. 45, N 3. P. 501–511.</mixed-citation></citation-alternatives></ref><ref id="B109"><label>109.</label><citation-alternatives><mixed-citation xml:lang="en">Matsuda H, Watanabe N, Kiso Y, et al. Necessity of IgE antibodies and mast cells for manifestation of resistance against larval Haemaphysalis longicornis ticks in mice. J Immunol. 1990; 144(1):259–262.</mixed-citation><mixed-citation xml:lang="ru">Matsuda H., Watanabe N., Kiso Y., et al. Necessity of IgE antibodies and mast cells for manifestation of resistance against larval Haemaphysalis longicornis ticks in mice // J Immunol. 1990. Vol. 144, N 1. P. 259–262.</mixed-citation></citation-alternatives></ref><ref id="B110"><label>110.</label><citation-alternatives><mixed-citation xml:lang="en">Wada T, Ishiwata K, Koseki H, et al. Selective ablation of basophils in mice reveals their nonredundant role in acquired immunity against ticks. J Clin Invest. 2010;120(8):2867–2875. doi: 10.1172/JCI42680</mixed-citation><mixed-citation xml:lang="ru">Wada T., Ishiwata K., Koseki H., et al. Selective ablation of basophils in mice reveals their nonredundant role in acquired immunity against ticks // J Clin Invest. 2010. Vol. 120, N 8. P. 2867–2875. doi: 10.1172/JCI42680</mixed-citation></citation-alternatives></ref><ref id="B111"><label>111.</label><citation-alternatives><mixed-citation xml:lang="en">Allen JR. Tick resistance: basophils in skin reactions of resistant guinea pigs. Int J Parasitol. 1973;3(2):195–200. doi: 10.1016/0020-7519(73)90024-6</mixed-citation><mixed-citation xml:lang="ru">Allen J.R. Tick resistance: basophils in skin reactions of resistant guinea pigs // Int J Parasitol. 1973. Vol. 3, N 2. P. 195–200. doi: 10.1016/0020-7519(73)90024-6</mixed-citation></citation-alternatives></ref><ref id="B112"><label>112.</label><citation-alternatives><mixed-citation xml:lang="en">Brown SJ, Askenase PW. Cutaneous basophil responses and immune resistance of guinea pigs to ticks: passive transfer with peritoneal exudate cells or serum. J Immunol. 1981;127(5):2163–2167.</mixed-citation><mixed-citation xml:lang="ru">Brown S.J., Askenase P.W. Cutaneous basophil responses and immune resistance of guinea pigs to ticks: passive transfer with peritoneal exudate cells or serum // J Immunol. 1981. Vol. 127, N 5. P. 2163–2167.</mixed-citation></citation-alternatives></ref><ref id="B113"><label>113.</label><citation-alternatives><mixed-citation xml:lang="en">Kimura R, Sugita K, Ito A, et al. Basophils are recruited and localized at the site of tick bites in humans. J Cutan Pathol. 2017;44(12):1091–1093. doi: 10.1111/cup.13045</mixed-citation><mixed-citation xml:lang="ru">Kimura R., Sugita K., Ito A., et al. Basophils are recruited and localized at the site of tick bites in humans // J Cutan Pathol. 2017. Vol. 44, N 12. P. 1091–1093. doi: 10.1111/cup.13045</mixed-citation></citation-alternatives></ref><ref id="B114"><label>114.</label><citation-alternatives><mixed-citation xml:lang="en">Brown SJ, Galli SJ, Gleich GJ, Askenase PW. Ablation of immunity to Amblyomma americanum by anti-basophil serum: cooperation between basophils and eosinophils in expression of immunity to ectoparasites (ticks) in guinea pigs. J Immunol. 1982; 129(2):790–796.</mixed-citation><mixed-citation xml:lang="ru">Brown S.J., Galli S.J., Gleich G.J., Askenase P.W. Ablation of immunity to Amblyomma americanum by anti-basophil serum: cooperation between basophils and eosinophils in expression of immunity to ectoparasites (ticks) in guinea pigs // J Immunol. 1982. Vol. 129, N 2. P. 790–796.</mixed-citation></citation-alternatives></ref><ref id="B115"><label>115.</label><citation-alternatives><mixed-citation xml:lang="en">Matsuda H, Fukui K, Kiso Y, Kitamura Y. Inability of genetically mast cell-deficient W/Wv mice to acquire resistance against larval Haemaphysalis longicornis ticks. J Parasitol. 1985;71(4):443–448.</mixed-citation><mixed-citation xml:lang="ru">Matsuda H., Fukui K., Kiso Y., Kitamura Y. Inability of genetically mast cell-deficient W/Wv mice to acquire resistance against larval Haemaphysalis longicornis ticks // J Parasitol. 1985. Vol. 71, N 4. P. 444–448.</mixed-citation></citation-alternatives></ref><ref id="B116"><label>116.</label><citation-alternatives><mixed-citation xml:lang="en">Matsuda H, Nakano T, Kiso Y, Kitamura Y. Normalization of anti-tick response of mast cell-deficient W/Wv mice by intracutaneous injection of cultured mast cells. J Parasitol. 1987;73(1):155–160.</mixed-citation><mixed-citation xml:lang="ru">Matsuda H., Nakano T., Kiso Y., Kitamura Y. Normalization of anti-tick response of mast cell-deficient W/Wv mice by intracutaneous injection of cultured mast cells // J Parasitol. 1987. Vol. 73, N 1. P. 155–160.</mixed-citation></citation-alternatives></ref><ref id="B117"><label>117.</label><citation-alternatives><mixed-citation xml:lang="en">Den Hollander N, Allen JR. Dermacentor variabilis: resistance to ticks acquired by mast cell-deficient and other strains of mice. Exp Parasitol. 1985;59(2):169–179. doi: 10.1016/0014-4894(85)90069-4</mixed-citation><mixed-citation xml:lang="ru">Den Hollander N., Allen J.R. Dermacentor variabilis: resistance to ticks acquired by mast cell-deficient and other strains of mice // Exp Parasitol. 1985. Vol. 59, N 2. P. 169–179. doi: 10.1016/0014-4894(85)90069-4</mixed-citation></citation-alternatives></ref><ref id="B118"><label>118.</label><citation-alternatives><mixed-citation xml:lang="en">Steeves EB, Allen JR. Tick resistance in mast cell-deficient mice: histological studies. Int J Parasitol. 1991;21(2):265–268. doi: 10.1016/0020-7519(91)90020-8</mixed-citation><mixed-citation xml:lang="ru">Steeves E.B., Allen J.R. Tick resistance in mast cell-deficient mice: histological studies // Int J Parasitol. 1991. Vol. 21, N 2. P. 265–268. doi: 10.1016/0020-7519(91)90020-8</mixed-citation></citation-alternatives></ref><ref id="B119"><label>119.</label><citation-alternatives><mixed-citation xml:lang="en">Karasuyama H, Miyake K, Yoshikawa S, et al. How do basophils contribute to Th2 cell differentiation and allergic responses? Int Immunol. 2018;30(9):391–396. doi: 10.1093/intimm/dxy026</mixed-citation><mixed-citation xml:lang="ru">Karasuyama H., Miyake K., Yoshikawa S., et al. How do basophils contribute to Th2 cell differentiation and allergic responses? // Int Immunol. 2018. Vol. 30, N 9. P. 391–396. doi: 10.1093/intimm/dxy026</mixed-citation></citation-alternatives></ref><ref id="B120"><label>120.</label><citation-alternatives><mixed-citation xml:lang="en">Kojima T, Obata K, Mukai K, et al. Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner. J Immunol. 2007;179(10):7093–7100. doi: 10.4049/jimmunol.179.10.7093</mixed-citation><mixed-citation xml:lang="ru">Kojima T., Obata K., Mukai K., et al. Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner // J Immunol. 2007. Vol. 179, N 10. P. 7093–7100. doi: 10.4049/jimmunol.179.10.7093</mixed-citation></citation-alternatives></ref><ref id="B121"><label>121.</label><citation-alternatives><mixed-citation xml:lang="en">Wikel SK. Histamine content of tick attachment sites and the effects of H1 and H2 histamine antagonists on the expression of resistance. Ann Trop Med Parasitol. 1982;76(2):179–85. doi: 10.1080/00034983.1982.11687525</mixed-citation><mixed-citation xml:lang="ru">Wikel S.K. Histamine content of tick attachment sites and the effects of H1 and H2 histamine antagonists on the expression of resistance // Ann Trop Med Parasitol. 1982. Vol. 76, N 2. P. 179–185. doi: 10.1080/00034983.1982.11687525</mixed-citation></citation-alternatives></ref><ref id="B122"><label>122.</label><citation-alternatives><mixed-citation xml:lang="en">Kemp DH, Bourne A. Boophilus microplus: the effect of histamine on the attachment of cattle-tick larvae--studies in vivo and in vitro. Parasitology. 1980;80(3):487–496. doi: 10.1017/s0031182000000950</mixed-citation><mixed-citation xml:lang="ru">Kemp D.H, Bourne A. Boophilus microplus: the effect of histamine on the attachment of cattle-tick larvae--studies in vivo and in vitro // Parasitology. 1980. Vol. 80, N 3. P. 487–496. doi: 10.1017/s0031182000000950</mixed-citation></citation-alternatives></ref><ref id="B123"><label>123.</label><citation-alternatives><mixed-citation xml:lang="en">Brossard M. Rabbits infested with adult Ixodes ricinus L.: effects of mepyramine on acquired resistance. Experientia. 1982; 38(6):702–704. doi: 10.1007/BF01964106</mixed-citation><mixed-citation xml:lang="ru">Brossard M. Rabbits infested with adult Ixodes ricinus L.: effects of mepyramine on acquired resistance // Experientia. 1982. Vol. 38, N 6. P. 702–704. doi: 10.1007/BF01964106</mixed-citation></citation-alternatives></ref><ref id="B124"><label>124.</label><citation-alternatives><mixed-citation xml:lang="en">Tabakawa Y, Ohta T, Yoshikawa S, et al. Histamine released from skin-infiltrating basophils but not mast cells is crucial for acquired tick resistance in mice. Front Immunol. 2018;9:1540. doi: 10.3389/fimmu.2018.01540</mixed-citation><mixed-citation xml:lang="ru">Tabakawa Y., Ohta T., Yoshikawa S., et al. Histamine released from skin-infiltrating basophils but not mast cells is crucial for acquired tick resistance in mice // Front Immunol. 2018. Vol. 9. P. 1540. doi: 10.3389/fimmu.2018.01540</mixed-citation></citation-alternatives></ref><ref id="B125"><label>125.</label><citation-alternatives><mixed-citation xml:lang="en">McCraw AJ, Chauhan J, Bax HJ, et al. Insights from IgE immune surveillance in allergy and cancer for anti-tumour ige treatments. Cancers (Basel). 2021;13(17):4460. doi: 10.3390/cancers13174460</mixed-citation><mixed-citation xml:lang="ru">McCraw A.J., Chauhan J., Bax H.J., et al. Insights from IgE immune surveillance in allergy and cancer for anti-tumour ige treatments // Cancers (Basel). 2021. Vol. 13, N 17. P. 4460. doi: 10.3390/cancers13174460</mixed-citation></citation-alternatives></ref><ref id="B126"><label>126.</label><citation-alternatives><mixed-citation xml:lang="en">Ure DM. Negative assoication between allergy and cancer. Scott Med J. 1969;14(2):51–54. doi: 10.1177/003693306901400203</mixed-citation><mixed-citation xml:lang="ru">Ure D.M. Negative assoication between allergy and cancer // Scott Med J. 1969. Vol. 14, N 2. P. 51–54. doi: 10.1177/003693306901400203</mixed-citation></citation-alternatives></ref><ref id="B127"><label>127.</label><citation-alternatives><mixed-citation xml:lang="en">Allegra J, Lipton A, Harvey H, et al. Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res. 1976;36(9 pt.1):3225–3226.</mixed-citation><mixed-citation xml:lang="ru">Allegra J., Lipton A., Harvey H., et al. Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population // Cancer Res. 1976. Vol. 36, N 9, pt. 1. P. 3225–3226.</mixed-citation></citation-alternatives></ref><ref id="B128"><label>128.</label><citation-alternatives><mixed-citation xml:lang="en">Augustin R, Chandradasa KD. IgE levels and allergic skin reactions in cancer and non-cancer patients. Int Arch Allergy Appl Immunol. 1971;41(1):141–143. doi: 10.1159/000230505</mixed-citation><mixed-citation xml:lang="ru">Augustin R., Chandradasa K.D. IgE levels and allergic skin reactions in cancer and non-cancer patients // Int Arch Allergy Appl Immunol. 1971. Vol. 41, N 1. P. 141–143. doi: 10.1159/000230505</mixed-citation></citation-alternatives></ref><ref id="B129"><label>129.</label><citation-alternatives><mixed-citation xml:lang="en">McCormick DP, Ammann AJ, Ishizaka K, et al. A study of allergy in patients with malignant lymphoma and chronic lymphocytic leukemia. Cancer. 1971;27(1):93–99. doi: 10.1002/1097-0142(197101)27:1&lt;93::aid-cncr2820270114&gt;3.0.co;2-0</mixed-citation><mixed-citation xml:lang="ru">McCormick D.P., Ammann A.J., Ishizaka K., et al. A study of allergy in patients with malignant lymphoma and chronic lymphocytic leukemia // Cancer. 1971. Vol. 27, N 1. P. 93–99. doi: 10.1002/1097-0142(197101)27:1&lt;93::aid-cncr2820270114&gt;3.0.co;2-0</mixed-citation></citation-alternatives></ref><ref id="B130"><label>130.</label><citation-alternatives><mixed-citation xml:lang="en">Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy. 2005;60(9):1098–1111. doi: 10.1111/j.1398-9995.2005.00813.x</mixed-citation><mixed-citation xml:lang="ru">Wang H., Diepgen T.L. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies // Allergy. 2005. Vol. 60, N 9. P. 1098–1111. doi: 10.1111/j.1398-9995.2005.00813.x</mixed-citation></citation-alternatives></ref><ref id="B131"><label>131.</label><citation-alternatives><mixed-citation xml:lang="en">Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61(9):1493–1510. doi: 10.1007/s00262-011-1180-6</mixed-citation><mixed-citation xml:lang="ru">Turner M.C. Epidemiology: allergy history, IgE, and cancer // Cancer Immunol Immunother. 2012. Vol. 61, N 9. P. 1493–1510. doi: 10.1007/s00262-011-1180-6</mixed-citation></citation-alternatives></ref><ref id="B132"><label>132.</label><citation-alternatives><mixed-citation xml:lang="en">Josephs DH, Spicer JF, Corrigan CJ, et al. Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy. 2013; 43(10):1110–1123. doi: 10.1111/cea.12178</mixed-citation><mixed-citation xml:lang="ru">Josephs D.H., Spicer J.F., Corrigan C.J., et al. Epidemiological associations of allergy, IgE and cancer // Clin Exp Allergy. 2013. Vol. 43, N 10. P. 1110–1123. doi: 10.1111/cea.12178</mixed-citation></citation-alternatives></ref><ref id="B133"><label>133.</label><citation-alternatives><mixed-citation xml:lang="en">Hayes MD, Ward S, Crawford G, et al. Inflammation-induced IgE promotes epithelial hyperplasia and tumour growth. Elife. 2020;9:e51862. doi: 10.7554/eLife.51862</mixed-citation><mixed-citation xml:lang="ru">Hayes M.D., Ward S., Crawford G., et al. Inflammation-induced IgE promotes epithelial hyperplasia and tumour growth // Elife. 2020. Vol. 9. P. e51862. doi: 10.7554/eLife.51862</mixed-citation></citation-alternatives></ref><ref id="B134"><label>134.</label><citation-alternatives><mixed-citation xml:lang="en">Karim AF, Westenberg LE, Eurelings LE, et al. The association between allergic diseases and cancer: a systematic review of the literature. Neth J Med. 2019;77(2):42–66.</mixed-citation><mixed-citation xml:lang="ru">Karim A.F., Westenberg L.E., Eurelings L.E., et al. The association between allergic diseases and cancer: a systematic review of the literature // Neth J Med. 2019. Vol. 77, N 2. P. 42–66.</mixed-citation></citation-alternatives></ref><ref id="B135"><label>135.</label><citation-alternatives><mixed-citation xml:lang="en">Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):158–171. doi: 10.1001/jamadermatol.2019.3786</mixed-citation><mixed-citation xml:lang="ru">Wang L., Bierbrier R., Drucker A.M., Chan A.W. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis // JAMA Dermatol. 2020. Vol. 156, N 2. P. 158–171. doi: 10.1001/jamadermatol.2019.3786</mixed-citation></citation-alternatives></ref><ref id="B136"><label>136.</label><citation-alternatives><mixed-citation xml:lang="en">Hemminki K, Försti A, Fallah M, et al. Risk of cancer in patients with medically diagnosed hay fever or allergic rhinitis. Int J Cancer. 2014;135(10):2397–2403. doi: 10.1002/ijc.28873</mixed-citation><mixed-citation xml:lang="ru">Hemminki K., Försti A., Fallah M., et al. Risk of cancer in patients with medically diagnosed hay fever or allergic rhinitis // Int J Cancer. 2014. Vol. 135, N 10. P. 2397–2403. doi: 10.1002/ijc.28873</mixed-citation></citation-alternatives></ref><ref id="B137"><label>137.</label><citation-alternatives><mixed-citation xml:lang="en">Kozłowska R, Bożek A, Jarząb J. Association between cancer and allergies. Allergy Asthma Clin Immunol. 2016;12:39. doi: 10.1186/s13223-016-0147-8</mixed-citation><mixed-citation xml:lang="ru">Kozłowska R., Bożek A., Jarząb J. Association between cancer and allergies // Allergy Asthma Clin Immunol. 2016. Vol. 12. P. 39. doi: 10.1186/s13223-016-0147-8</mixed-citation></citation-alternatives></ref><ref id="B138"><label>138.</label><citation-alternatives><mixed-citation xml:lang="en">Rosenberger A, Bickeböller H, McCormack V, et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis. 2012;33(3):587–597. doi: 10.1093/carcin/bgr307</mixed-citation><mixed-citation xml:lang="ru">Rosenberger A., Bickeböller H., McCormack V., et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium // Carcinogenesis. 2012. Vol. 33, N 3. P. 587–597. doi: 10.1093/carcin/bgr307</mixed-citation></citation-alternatives></ref><ref id="B139"><label>139.</label><citation-alternatives><mixed-citation xml:lang="en">Rittmeyer D, Lorentz A. Relationship between allergy and cancer: an overview. Int Arch Allergy Immunol. 2012;159(3):216–225. doi: 10.1159/000338994</mixed-citation><mixed-citation xml:lang="ru">Rittmeyer D., Lorentz A. Relationship between allergy and cancer: an overview // Int Arch Allergy Immunol. 2012. Vol. 159, N 3. P. 216–225. doi: 10.1159/000338994</mixed-citation></citation-alternatives></ref><ref id="B140"><label>140.</label><citation-alternatives><mixed-citation xml:lang="en">Ji J, Shu X, Li X, et al. Cancer risk in hospitalised asthma patients. Br J Cancer. 2009;100(5):829–833. doi: 10.1038/sj.bjc.6604890</mixed-citation><mixed-citation xml:lang="ru">Ji J., Shu X., Li X., et al. Cancer risk in hospitalised asthma patients // Br J Cancer. 2009. Vol. 100, N 5. P. 829–833. doi: 10.1038/sj.bjc.6604890</mixed-citation></citation-alternatives></ref><ref id="B141"><label>141.</label><citation-alternatives><mixed-citation xml:lang="en">Arana A, Wentworth CE, Fernández-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036–1043. doi: 10.1111/j.1365-2133.2010.09887.x</mixed-citation><mixed-citation xml:lang="ru">Arana A., Wentworth C.E., Fernández-Vidaurre C., et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K // Br J Dermatol. 2010. Vol. 163, N 5. P. 1036–1043. doi: 10.1111/j.1365-2133.2010.09887.x</mixed-citation></citation-alternatives></ref><ref id="B142"><label>142.</label><citation-alternatives><mixed-citation xml:lang="en">Talbot-Smith A, Fritschi L, Divitini ML, et al. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol. 2003;157(7):606–612. doi: 10.1093/aje/kwg020</mixed-citation><mixed-citation xml:lang="ru">Talbot-Smith A., Fritschi L., Divitini M.L., et al. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort // Am J Epidemiol. 2003. Vol. 157, N 7. P. 606–612. doi: 10.1093/aje/kwg020</mixed-citation></citation-alternatives></ref><ref id="B143"><label>143.</label><citation-alternatives><mixed-citation xml:lang="en">Gandini S, Stanganelli I, Palli D, et al. Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis. J Dermatol Sci. 2016;84(2):137–143. doi: 10.1016/j.jdermsci.2016.07.009</mixed-citation><mixed-citation xml:lang="ru">Gandini S., Stanganelli I., Palli D., et al. Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis // J Dermatol Sci. 2016. Vol. 84, N 2. P. 137–143. doi: 10.1016/j.jdermsci.2016.07.009</mixed-citation></citation-alternatives></ref><ref id="B144"><label>144.</label><citation-alternatives><mixed-citation xml:lang="en">Jensen AO, Svaerke C, Körmendiné Farkas D, et al. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012;13(1):29–36. doi: 10.2165/11593280-000000000-00000</mixed-citation><mixed-citation xml:lang="ru">Jensen A.O., Svaerke C., Körmendiné Farkas D., et al. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006) // Am J Clin Dermatol. 2012. Vol. 13, N 1. P. 29–36. doi: 10.2165/11593280-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="B145"><label>145.</label><citation-alternatives><mixed-citation xml:lang="en">Hwang CY, Chen YJ, Lin MW, et al. Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan. Int J Cancer. 2012;130(5):1160–1167. doi: 10.1002/ijc.26105</mixed-citation><mixed-citation xml:lang="ru">Hwang C.Y., Chen Y.J., Lin M.W., et al. Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan // Int J Cancer. 2012. Vol. 130, N 5. P. 1160–1167. doi: 10.1002/ijc.26105</mixed-citation></citation-alternatives></ref><ref id="B146"><label>146.</label><citation-alternatives><mixed-citation xml:lang="en">Wiemels JL, Wiencke JK, Li Z, et al. Risk of squamous cell carcinoma of the skin in relation to IgE: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2377–2383. doi: 10.1158/1055-9965.EPI-11-0668</mixed-citation><mixed-citation xml:lang="ru">Wiemels J.L., Wiencke J.K., Li Z., et al. Risk of squamous cell carcinoma of the skin in relation to IgE: a nested case-control study // Cancer Epidemiol Biomarkers Prev. 2011. Vol. 20, N 11. P. 2377–2383. doi: 10.1158/1055-9965.EPI-11-0668</mixed-citation></citation-alternatives></ref><ref id="B147"><label>147.</label><citation-alternatives><mixed-citation xml:lang="en">Cheng J, Zens MS, Duell E, et al. History of allergy and atopic dermatitis in relation to squamous cell and Basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2015;24(4):749–754. doi: 10.1158/1055-9965.EPI-14-1243</mixed-citation><mixed-citation xml:lang="ru">Cheng J., Zens M.S., Duell E., et al. History of allergy and atopic dermatitis in relation to squamous cell and Basal cell carcinoma of the skin // Cancer Epidemiol Biomarkers Prev. 2015. Vol. 24, N 4. P. 749–754. doi: 10.1158/1055-9965.EPI-14-1243</mixed-citation></citation-alternatives></ref><ref id="B148"><label>148.</label><citation-alternatives><mixed-citation xml:lang="en">Wulaningsih W, Holmberg L, Garmo H, et al. Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. Oncoimmunology. 2016;5(6):e1154250. doi: 10.1080/2162402X.2016.1154250</mixed-citation><mixed-citation xml:lang="ru">Wulaningsih W., Holmberg L., Garmo H., et al. Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival // Oncoimmunology. 2016. Vol. 5, N 6. P. e1154250. doi: 10.1080/2162402X.2016.1154250</mixed-citation></citation-alternatives></ref><ref id="B149"><label>149.</label><citation-alternatives><mixed-citation xml:lang="en">Halling-Overgaard AS, Ravnborg N, Silverberg JI, et al. Atopic dermatitis and cancer in solid organs: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(2):e81–e82. doi: 10.1111/jdv.15230</mixed-citation><mixed-citation xml:lang="ru">Halling-Overgaard A.S., Ravnborg N., Silverberg J.I., et al. Atopic dermatitis and cancer in solid organs: a systematic review and meta-analysis // J Eur Acad Dermatol Venereol. 2019. Vol. 33, N 2. P. e81–e82. doi: 10.1111/jdv.15230</mixed-citation></citation-alternatives></ref><ref id="B150"><label>150.</label><citation-alternatives><mixed-citation xml:lang="en">Merrill RM, Isakson RT, Beck RE. The association between allergies and cancer: what is currently known? Ann Allergy Asthma Immunol. 2007;99(2):102–116; quiz 117-9, 150. doi: 10.1016/S1081-1206(10)60632-1</mixed-citation><mixed-citation xml:lang="ru">Merrill R.M., Isakson R.T., Beck R.E. The association between allergies and cancer: what is currently known? // Ann Allergy Asthma Immunol. 2007. Vol. 99, N 2. P. 102–116; quiz 117-9, 150. doi: 10.1016/S1081-1206(10)60632-1</mixed-citation></citation-alternatives></ref><ref id="B151"><label>151.</label><citation-alternatives><mixed-citation xml:lang="en">Bosetti C, Talamini R, Franceschi S, et al. Allergy and the risk of selected digestive and laryngeal neoplasms. Eur J Cancer Prev. 2004;13(3):173–176. doi: 10.1097/01.cej.0000130016.85687.cf</mixed-citation><mixed-citation xml:lang="ru">Bosetti C., Talamini R., Franceschi S., et al. Allergy and the risk of selected digestive and laryngeal neoplasms // Eur J Cancer Prev. 2004. Vol. 13, N 3. P. 173–176. doi: 10.1097/01.cej.0000130016.85687.cf</mixed-citation></citation-alternatives></ref><ref id="B152"><label>152.</label><citation-alternatives><mixed-citation xml:lang="en">Fereidouni M, Ferns GA, Bahrami A. Current status and perspectives regarding the association between allergic disorders and cancer. IUBMB Life. 2020;72(7):1322–1339. doi: 10.1002/iub.2285</mixed-citation><mixed-citation xml:lang="ru">Fereidouni M., Ferns G.A., Bahrami A. Current status and perspectives regarding the association between allergic disorders and cancer // IUBMB Life. 2020. Vol. 72, N 7. P. 1322–1339. doi: 10.1002/iub.2285</mixed-citation></citation-alternatives></ref><ref id="B153"><label>153.</label><citation-alternatives><mixed-citation xml:lang="en">Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol. 1993; 22(6):976–982. doi: 10.1093/ije/22.6.976</mixed-citation><mixed-citation xml:lang="ru">Vesterinen E., Pukkala E., Timonen T., Aromaa A. Cancer incidence among 78,000 asthmatic patients // Int J Epidemiol. 1993. Vol. 22, N 6. P. 976–982. doi: 10.1093/ije/22.6.976</mixed-citation></citation-alternatives></ref><ref id="B154"><label>154.</label><citation-alternatives><mixed-citation xml:lang="en">Amirian ES, Marquez-Do D, Bondy ML, Scheurer ME. Antihistamine use and immunoglobulin E levels in glioma risk and prognosis. Cancer Epidemiol. 2013;37(6):908–912. doi: 10.1016/j.canep.2013.08.004</mixed-citation><mixed-citation xml:lang="ru">Amirian E.S., Marquez-Do D., Bondy M.L. Scheurer M.E. Antihistamine use and immunoglobulin E levels in glioma risk and prognosis // Cancer Epidemiol. 2013. Vol. 37, N 6. P. 908–912. doi: 10.1016/j.canep.2013.08.004</mixed-citation></citation-alternatives></ref><ref id="B155"><label>155.</label><citation-alternatives><mixed-citation xml:lang="en">McCarthy BJ, Rankin K, Il’yasova D, et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev. 2011;20(2):370–378. doi: 10.1158/1055-9965</mixed-citation><mixed-citation xml:lang="ru">McCarthy B.J., Rankin K., Il’yasova D., et al. Assessment of type of allergy and antihistamine use in the development of glioma // Cancer Epidemiol Biomarkers Prev. 2011. Vol. 20, N 2. P. 370–378. doi: 10.1158/1055-9965</mixed-citation></citation-alternatives></ref><ref id="B156"><label>156.</label><citation-alternatives><mixed-citation xml:lang="en">Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544–1550. doi: 10.1093/jnci/djm170</mixed-citation><mixed-citation xml:lang="ru">Linos E., Raine T., Alonso A., Michaud D. Atopy and risk of brain tumors: a meta-analysis // J Natl Cancer Inst. 2007. Vol. 99, N 20. P. 1544–1550. doi: 10.1093/jnci/djm170</mixed-citation></citation-alternatives></ref><ref id="B157"><label>157.</label><citation-alternatives><mixed-citation xml:lang="en">Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol. 2021;14(4):101029. doi: 10.1016/j.tranon.2021.101029</mixed-citation><mixed-citation xml:lang="ru">Fritz I., Wagner P., Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine // Transl Oncol. 2021. Vol. 14, N 4. P. 101029. doi: 10.1016/j.tranon.2021.101029</mixed-citation></citation-alternatives></ref><ref id="B158"><label>158.</label><citation-alternatives><mixed-citation xml:lang="en">Van Hemelrijck M, Garmo H, Binda E, et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control. 2010;21(10):1657–1667. doi: 10.1007/s10552-010-9594-6</mixed-citation><mixed-citation xml:lang="ru">Van Hemelrijck M., Garmo H., Binda E., et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study // Cancer Causes Control. 2010. Vol. 21, N 10. P. 1657–1667. doi: 10.1007/s10552-010-9594-6</mixed-citation></citation-alternatives></ref><ref id="B159"><label>159.</label><citation-alternatives><mixed-citation xml:lang="en">Calboli FC, Cox DG, Buring JE, et al. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst. 2011;103(21):1588–1595. doi: 10.1093/jnci/djr361</mixed-citation><mixed-citation xml:lang="ru">Calboli F.C., Cox D.G., Buring J.E., et al. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies // J Natl Cancer Inst. 2011. Vol. 103, N 21. P. 1588–1595. doi: 10.1093/jnci/djr361</mixed-citation></citation-alternatives></ref><ref id="B160"><label>160.</label><citation-alternatives><mixed-citation xml:lang="en">Wiemels JL, Wiencke JK, Patoka J, et al. Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res. 2004;64(22):8468–8473. doi: 10.1158/0008-5472</mixed-citation><mixed-citation xml:lang="ru">Wiemels J.L., Wiencke J.K., Patoka J., et al. Reduced immunoglobulin E and allergy among adults with glioma compared with controls // Cancer Res. 2004. Vol. 64, N 22. P. 8468–8473. doi: 10.1158/0008-5472</mixed-citation></citation-alternatives></ref><ref id="B161"><label>161.</label><citation-alternatives><mixed-citation xml:lang="en">Nieters A, Łuczyńska A, Becker S, et al. Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition. Carcinogenesis. 2014;35(12):2716–2722. doi: 10.1093/carcin/bgu188</mixed-citation><mixed-citation xml:lang="ru">Nieters A., Łuczyńska A., Becker S., et al. Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition // Carcinogenesis. 2014. Vol. 35, N 12. P. 2716–2722. doi: 10.1093/carcin/bgu188</mixed-citation></citation-alternatives></ref><ref id="B162"><label>162.</label><citation-alternatives><mixed-citation xml:lang="en">Ferastraoaru D, Bax HJ, Bergmann C, et al. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy. 2020;10:32. doi: 10.1186/s13601-020-00335-w</mixed-citation><mixed-citation xml:lang="ru">Ferastraoaru D., Bax H.J., Bergmann C., et al. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) // Clin Transl Allergy. 2020. Vol. 10. P. 32. doi: 10.1186/s13601-020-00335-w</mixed-citation></citation-alternatives></ref><ref id="B163"><label>163.</label><citation-alternatives><mixed-citation xml:lang="en">Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008;63(10): 1255–1266. doi: 10.1111/j.1398-9995.2008.01768.x</mixed-citation><mixed-citation xml:lang="ru">Jensen-Jarolim E., Achatz G., Turner M.C., et al. AllergoOncology: the role of IgE-mediated allergy in cancer // Allergy. 2008. Vol. 63, N 10. P. 1255–1266. doi: 10.1111/j.1398-9995.2008.01768.x</mixed-citation></citation-alternatives></ref><ref id="B164"><label>164.</label><citation-alternatives><mixed-citation xml:lang="en">Singer J, Achatz-Straussberger G, Bentley-Lukschal A, et al. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. World Allergy Organ J. 2019;12(7):100044. doi: 10.1016/j.waojou.2019.100044</mixed-citation><mixed-citation xml:lang="ru">Singer J., Achatz-Straussberger G., Bentley-Lukschal A., et al. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice // World Allergy Organ J. 2019. Vol. 12, N 7. P. 100044. doi: 10.1016/j.waojou.2019.100044</mixed-citation></citation-alternatives></ref><ref id="B165"><label>165.</label><citation-alternatives><mixed-citation xml:lang="en">Fu SL, Pierre J, Smith-Norowitz TA, et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol. 2008;153(3):401–409. doi: 10.1111/j.1365-2249.2008.03726.x</mixed-citation><mixed-citation xml:lang="ru">Fu S.L., Pierre J., Smith-Norowitz T.A., et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells // Clin Exp Immunol. 2008. Vol. 153, N 3. P. 401–409. doi: 10.1111/j.1365-2249.2008.03726.x</mixed-citation></citation-alternatives></ref><ref id="B166"><label>166.</label><citation-alternatives><mixed-citation xml:lang="en">Daniels TR, Leuchter RK, Quintero R, et al. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother. 2012;61(7):991–1003. doi: 10.1007/s00262-011-1150-z</mixed-citation><mixed-citation xml:lang="ru">Daniels T.R., Leuchter R.K., Quintero R., et al. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells // Cancer Immunol Immunother. 2012. Vol. 61, N 7. P. 991–1003. doi: 10.1007/s00262-011-1150-z</mixed-citation></citation-alternatives></ref><ref id="B167"><label>167.</label><citation-alternatives><mixed-citation xml:lang="en">Karagiannis P, Singer J, Hunt J, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother. 2009;58(6):915–930. doi: 10.1007/s00262-008-0607-1</mixed-citation><mixed-citation xml:lang="ru">Karagiannis P., Singer J., Hunt J., et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells // Cancer Immunol Immunother. 2009. Vol. 58, N 6. P. 915–930. doi: 10.1007/s00262-008-0607-1</mixed-citation></citation-alternatives></ref><ref id="B168"><label>168.</label><citation-alternatives><mixed-citation xml:lang="en">Spillner E, Plum M, Blank S, et al. Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother. 2012; 61(9):1565–1573. doi: 10.1007/s00262-012-1287-4</mixed-citation><mixed-citation xml:lang="ru">Spillner E., Plum M., Blank S., et al. Recombinant IgE antibody engineering to target EGFR // Cancer Immunol Immunother. 2012. Vol. 61, N 9. P. 1565–1573. doi: 10.1007/s00262-012-1287-4</mixed-citation></citation-alternatives></ref><ref id="B169"><label>169.</label><citation-alternatives><mixed-citation xml:lang="en">Chauhan J, McCraw AJ, Nakamura M, et al. IgE Antibodies against Cancer: Efficacy and Safety. Antibodies (Basel). 2020; 9(4):55. doi: 10.3390/antib9040055</mixed-citation><mixed-citation xml:lang="ru">Chauhan J., McCraw A.J., Nakamura M., et al. IgE Antibodies against Cancer: Efficacy and Safety // Antibodies (Basel). 2020. Vol. 9, N 4. P. 55. doi: 10.3390/antib9040055</mixed-citation></citation-alternatives></ref><ref id="B170"><label>170.</label><citation-alternatives><mixed-citation xml:lang="en">Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–989.e6. doi: 10.1016/j.jaci.2012.01.033</mixed-citation><mixed-citation xml:lang="ru">Busse W., Buhl R., Fernandez Vidaurre C., et al. Omalizumab and the risk of malignancy: results from a pooled analysis // J Allergy Clin Immunol. 2012. Vol. 129, N 4. P. 983–989.e6. doi: 10.1016/j.jaci.2012.01.033</mixed-citation></citation-alternatives></ref><ref id="B171"><label>171.</label><citation-alternatives><mixed-citation xml:lang="en">Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567.e4. doi: 10.1016/j.jaci.2014.02.007</mixed-citation><mixed-citation xml:lang="ru">Long A., Rahmaoui A., Rothman K.J., et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab // J Allergy Clin Immunol. 2014. Vol. 134, N 3. P. 560–567.e4. doi: 10.1016/j.jaci.2014.02.007</mixed-citation></citation-alternatives></ref><ref id="B172"><label>172.</label><citation-alternatives><mixed-citation xml:lang="en">Johnston A, Smith C, Zheng C, et al. Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta-analysis. Clin Exp Allergy. 2019;49(10):1291–1305. doi: 10.1111/cea.13457</mixed-citation><mixed-citation xml:lang="ru">Johnston A., Smith C., Zheng C., et al. Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta-analysis // Clin Exp Allergy. 2019. Vol. 49, N 10. P. 1291–1305. doi: 10.1111/cea.13457</mixed-citation></citation-alternatives></ref><ref id="B173"><label>173.</label><citation-alternatives><mixed-citation xml:lang="en">Mota D, Rama TA, Severo M, Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Allergy. 2021;76(10): 3209–3211. doi: 10.1111/all.15008</mixed-citation><mixed-citation xml:lang="ru">Mota D., Rama T.A., Severo M., Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database // Allergy. 2021. Vol. 76, N 10. P. 3209–3211. doi: 10.1111/all.15008</mixed-citation></citation-alternatives></ref><ref id="B174"><label>174.</label><citation-alternatives><mixed-citation xml:lang="en">Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: a pitch for multiple players. Front Oncol. 2013;3:90. doi: 10.3389/fonc.2013.00090</mixed-citation><mixed-citation xml:lang="ru">Schiavoni G., Gabriele L., Mattei F. The tumor microenvironment: a pitch for multiple players // Front Oncol. 2013. Vol. 3. P. 90. doi: 10.3389/fonc.2013.00090</mixed-citation></citation-alternatives></ref><ref id="B175"><label>175.</label><citation-alternatives><mixed-citation xml:lang="en">Lyons DO, Pullen NA. Beyond IgE: Alternative Mast Cell Activation Across Different Disease States. Int J Mol Sci. 2020;21(4):1498. doi: 10.3390/ijms21041498</mixed-citation><mixed-citation xml:lang="ru">Lyons D.O., Pullen N.A. Beyond IgE: Alternative Mast Cell Activation Across Different Disease States // Int J Mol Sci. 2020. Vol. 21, N 4. P. 1498. doi: 10.3390/ijms21041498</mixed-citation></citation-alternatives></ref><ref id="B176"><label>176.</label><citation-alternatives><mixed-citation xml:lang="en">Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322. doi: 10.1016/j.ccr.2012.02.022</mixed-citation><mixed-citation xml:lang="ru">Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment // Cancer Cell. 2012. Vol. 21, N 3. P. 309–322. doi: 10.1016/j.ccr.2012.02.022. PMID: 22439926</mixed-citation></citation-alternatives></ref><ref id="B177"><label>177.</label><citation-alternatives><mixed-citation xml:lang="en">Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107(2):249–257. doi: 10.1007/s10549-007-9546-3</mixed-citation><mixed-citation xml:lang="ru">Rajput A.B., Turbin D.A., Cheang M.C., et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases // Breast Cancer Res Treat. 2008. Vol. 107, N 2. P. 249–257. doi: 10.1007/s10549-007-9546-3</mixed-citation></citation-alternatives></ref><ref id="B178"><label>178.</label><citation-alternatives><mixed-citation xml:lang="en">Benyon RC, Bissonnette EY, Befus AD. Tumor necrosis factor-alpha dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. J Immunol. 1991;147(7):2253–2258.</mixed-citation><mixed-citation xml:lang="ru">Benyon R.C., Bissonnette E.Y., Befus A.D. Tumor necrosis factor-alpha dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies // J Immunol. 1991. Vol. 147, N 7. P. 2253–2258.</mixed-citation></citation-alternatives></ref><ref id="B179"><label>179.</label><citation-alternatives><mixed-citation xml:lang="en">Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res. 1997;17(3A):1541–1549.</mixed-citation><mixed-citation xml:lang="ru">Dimitriadou V., Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? // Anticancer Res. 1997. Vol. 17, N 3A. P. 1541–1549.</mixed-citation></citation-alternatives></ref><ref id="B180"><label>180.</label><citation-alternatives><mixed-citation xml:lang="en">Mehdawi L, Osman J, Topi G, Sjölander A. High tumor mast cell density is associated with longer survival of colon cancer patients. Acta Oncol. 2016;55(12):1434–1442. doi: 10.1080/0284186X.2016.1198493</mixed-citation><mixed-citation xml:lang="ru">Mehdawi L., Osman J., Topi G., Sjölander A. High tumor mast cell density is associated with longer survival of colon cancer patients // Acta Oncol. 2016. Vol. 55, N 12. P. 1434–1442. doi: 10.1080/0284186X.2016.1198493</mixed-citation></citation-alternatives></ref><ref id="B181"><label>181.</label><citation-alternatives><mixed-citation xml:lang="en">Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031–1041. doi: 10.2353/ajpath.2010.100070</mixed-citation><mixed-citation xml:lang="ru">Johansson A., Rudolfsson S., Hammarsten P., et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy // Am J Pathol. 2010. Vol. 177, N 2. P. 1031–1041. doi: 10.2353/ajpath.2010.100070</mixed-citation></citation-alternatives></ref><ref id="B182"><label>182.</label><citation-alternatives><mixed-citation xml:lang="en">Siiskonen H, Poukka M, Bykachev A, et al. Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma. Melanoma Res. 2015;25(6):479–485. doi: 10.1097/CMR.0000000000000192</mixed-citation><mixed-citation xml:lang="ru">Siiskonen H., Poukka M., Bykachev A., et al. Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma // Melanoma Res. 2015. Vol. 25, N 6. P. 479–485. doi: 10.1097/CMR.0000000000000192</mixed-citation></citation-alternatives></ref><ref id="B183"><label>183.</label><citation-alternatives><mixed-citation xml:lang="en">Pittoni P, Tripodo C, Piconese S, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011;71(18):5987–5997. doi: 10.1158/0008-5472.CAN-11-1637</mixed-citation><mixed-citation xml:lang="ru">Pittoni P., Tripodo C., Piconese S., et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers // Cancer Res. 2011. Vol. 71, N 18. P. 5987–5997. doi: 10.1158/0008-5472.CAN-11-1637</mixed-citation></citation-alternatives></ref><ref id="B184"><label>184.</label><citation-alternatives><mixed-citation xml:lang="en">Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012;72(4):831–835. doi: 10.1158/0008-5472.CAN-11-3110</mixed-citation><mixed-citation xml:lang="ru">Pittoni P., Colombo M.P. The dark side of mast cell-targeted therapy in prostate cancer // Cancer Res. 2012. Vol. 72, N 4. P. 831–835. doi: 10.1158/0008-5472.CAN-11-3110</mixed-citation></citation-alternatives></ref><ref id="B185"><label>185.</label><citation-alternatives><mixed-citation xml:lang="en">Carlini MJ, Dalurzo MC, Lastiri JM, et al. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol. 2010;41(5):697–705. doi: 10.1016/j.humpath.2009.04.029</mixed-citation><mixed-citation xml:lang="ru">Carlini M.J., Dalurzo M.C., Lastiri J.M., et al. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance // Hum Pathol. 2010. Vol. 41, N 5. P. 697–705. doi: 10.1016/j.humpath.2009.04.029</mixed-citation></citation-alternatives></ref><ref id="B186"><label>186.</label><citation-alternatives><mixed-citation xml:lang="en">Grimbaldeston MA, Pearce AL, Robertson BO, et al. Association between melanoma and dermal mast cell prevalence in sun-unexposed skin. Br J Dermatol. 2004;150(5):895–903. doi: 10.1111/j.1365-2133.2004.05966.x</mixed-citation><mixed-citation xml:lang="ru">Grimbaldeston M.A., Pearce A.L., Robertson B.O., et al. Association between melanoma and dermal mast cell prevalence in sun-unexposed skin // Br J Dermatol. 2004. Vol. 150, N 5. P. 895–903. doi: 10.1111/j.1365-2133.2004.05966.x</mixed-citation></citation-alternatives></ref><ref id="B187"><label>187.</label><citation-alternatives><mixed-citation xml:lang="en">Grujic M, Paivandy A, Gustafson AM, et al. The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung. Oncotarget. 2017;8(15):25066–25079. doi: 10.18632/oncotarget.15339</mixed-citation><mixed-citation xml:lang="ru">Grujic M., Paivandy A., Gustafson A.M., et al. The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung // Oncotarget. 2017. Vol. 8, N 15. P. 25066–25079. doi: 10.18632/oncotarget.15339</mixed-citation></citation-alternatives></ref><ref id="B188"><label>188.</label><citation-alternatives><mixed-citation xml:lang="en">Caruso RA, Fedele F, Zuccalà V, et al. Mast cell and eosinophil interaction in gastric carcinomas: ultrastructural observations. Anticancer Res. 2007;27(1A):391–394.</mixed-citation><mixed-citation xml:lang="ru">Caruso R.A., Fedele F., Zuccalà V., et al. Mast cell and eosinophil interaction in gastric carcinomas: ultrastructural observations // Anticancer Res. 2007. Vol. 27, N 1A. P. 391–394.</mixed-citation></citation-alternatives></ref><ref id="B189"><label>189.</label><citation-alternatives><mixed-citation xml:lang="en">Da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698–738. doi: 10.1369/0022155414545334</mixed-citation><mixed-citation xml:lang="ru">Da Silva E.Z., Jamur M.C., Oliver C. Mast cell function: a new vision of an old cell // J Histochem Cytochem. 2014. Vol. 62, N 10. P. 698–738. doi: 10.1369/0022155414545334</mixed-citation></citation-alternatives></ref><ref id="B190"><label>190.</label><citation-alternatives><mixed-citation xml:lang="en">Dyduch G, Kaczmarczyk K, Okoń K. Mast cells and cancer: enemies or allies? Pol J Pathol. 2012;63(1):1–7.</mixed-citation><mixed-citation xml:lang="ru">Dyduch G., Kaczmarczyk K., Okoń K. Mast cells and cancer: enemies or allies? // Pol J Pathol. 2012. Vol. 63, N 1. P. 1–7.</mixed-citation></citation-alternatives></ref><ref id="B191"><label>191.</label><citation-alternatives><mixed-citation xml:lang="en">Poncin A, Onesti CE, Josse C, et al. Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines. 2021;9(9):1087. doi: 10.3390/biomedicines9091087</mixed-citation><mixed-citation xml:lang="ru">Poncin A., Onesti C.E., Josse C., et al. Immunity and Breast Cancer: Focus on Eosinophils // Biomedicines. 2021. Vol. 9, N 9. P. 1087. doi: 10.3390/biomedicines9091087</mixed-citation></citation-alternatives></ref><ref id="B192"><label>192.</label><citation-alternatives><mixed-citation xml:lang="en">Mattei F, Andreone S, Marone G, et al. Eosinophils in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:1–28. doi: 10.1007/978-3-030-49270-0_1</mixed-citation><mixed-citation xml:lang="ru">Mattei F., Andreone S., Marone G., et al. Eosinophils in the tumor microenvironment // Adv Exp Med Biol. 2020. Vol. 1273. P. 1–28. doi: 10.1007/978-3-030-49270-0_1</mixed-citation></citation-alternatives></ref><ref id="B193"><label>193.</label><citation-alternatives><mixed-citation xml:lang="en">Caruso RA, Branca G, Fedele F, et al. Eosinophil-Specific granules in tumor cell cytoplasm: unusual ultrastructural findings in a case of diffuse-type gastric carcinoma. Ultrastruct Pathol. 2015;39(4):226–230. doi: 10.3109/01913123.2014.991886</mixed-citation><mixed-citation xml:lang="ru">Caruso R.A., Branca G., Fedele F., et al. Eosinophil-Specific granules in tumor cell cytoplasm: unusual ultrastructural findings in a case of diffuse-type gastric carcinoma // Ultrastruct Pathol. 2015. Vol. 39, N 4. P. 226–230. doi: 10.3109/01913123.2014.991886</mixed-citation></citation-alternatives></ref><ref id="B194"><label>194.</label><citation-alternatives><mixed-citation xml:lang="en">Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594–607. doi: 10.1038/s41568-020-0283-9</mixed-citation><mixed-citation xml:lang="ru">Grisaru-Tal S., Itan M., Klion A.D., Munitz A. A new dawn for eosinophils in the tumour microenvironment // Nat Rev Cancer. 2020. Vol. 20, N 10. P. 594–607. doi: 10.1038/s41568-020-0283-9</mixed-citation></citation-alternatives></ref><ref id="B195"><label>195.</label><citation-alternatives><mixed-citation xml:lang="en">Kanda A, Yasutaka Y, Van Bui D, et al. Multiple biological aspects of eosinophils in host defense, eosinophil-associated diseases, immunoregulation, and homeostasis: is their role beneficial, detrimental, regulator, or bystander? Biol Pharm Bull. 2020; 43(1):20–30. doi: 10.1248/bpb.b19-00892</mixed-citation><mixed-citation xml:lang="ru">Kanda A., Yasutaka Y., Van Bui D., et al. Multiple biological aspects of eosinophils in host defense, eosinophil-associated diseases, immunoregulation, and homeostasis: is their role beneficial, detrimental, regulator, or bystander? // Biol Pharm Bull. 2020. Vol. 43, N 1. P. 20–30. doi: 10.1248/bpb.b19-00892</mixed-citation></citation-alternatives></ref><ref id="B196"><label>196.</label><citation-alternatives><mixed-citation xml:lang="en">Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer. 1986;58(6):1321–1327. doi: 10.1002/1097-0142(19860915)58:6&lt;1321::aid-cncr2820580623&gt;3.0.co;2-o</mixed-citation><mixed-citation xml:lang="ru">Iwasaki K., Torisu M., Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer // Cancer. 1986. Vol. 58, N 6. P. 1321–1327. doi: 10.1002/1097-0142(19860915)58:6&lt;1321::aid-cncr2820580623&gt;3.0.co;2-o</mixed-citation></citation-alternatives></ref><ref id="B197"><label>197.</label><citation-alternatives><mixed-citation xml:lang="en">Jong EC, Klebanoff SJ. Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system. J Immunol. 1980;124(4):1949–1953.</mixed-citation><mixed-citation xml:lang="ru">Jong E.C., Klebanoff S.J. Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system // J Immunol. 1980. Vol. 124, N 4. P. 1949–1953.</mixed-citation></citation-alternatives></ref><ref id="B198"><label>198.</label><citation-alternatives><mixed-citation xml:lang="en">Reichman H, Itan M, Rozenberg P, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7(3):388–400. doi: 10.1158/2326-6066.CIR-18-0494</mixed-citation><mixed-citation xml:lang="ru">Reichman H., Itan M., Rozenberg P., et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer // Cancer Immunol Res. 2019. Vol. 7, N 3. P. 388–400. doi: 10.1158/2326-6066.CIR-18-0494</mixed-citation></citation-alternatives></ref><ref id="B199"><label>199.</label><citation-alternatives><mixed-citation xml:lang="en">Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018; 13(1):97–105. doi: 10.1016/j.jtho.2017.10.030</mixed-citation><mixed-citation xml:lang="ru">Tanizaki J., Haratani K., Hayashi H., et al. peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab // J Thorac Oncol. 2018. Vol. 13, N 1. P. 97–105. doi: 10.1016/j.jtho.2017.10.030</mixed-citation></citation-alternatives></ref><ref id="B200"><label>200.</label><citation-alternatives><mixed-citation xml:lang="en">Dorta RG, Landman G, Kowalski LP, et al. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology. 2002;41(2):152–157. doi: 10.1046/j.1365-2559.2002.01437.x</mixed-citation><mixed-citation xml:lang="ru">Dorta R.G., Landman G., Kowalski L.P., et al. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas // Histopathology. 2002. Vol. 41, N 2. P. 152–157. doi: 10.1046/j.1365-2559.2002.01437.x</mixed-citation></citation-alternatives></ref><ref id="B201"><label>201.</label><citation-alternatives><mixed-citation xml:lang="en">da Silva JM, Queiroz-Junior CM, Batista AC, et al. Eosinophil depletion protects mice from tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide. Histol Histopathol. 2014;29(3):387–396. doi: 10.14670/HH-29.387</mixed-citation><mixed-citation xml:lang="ru">Da Silva J.M., Queiroz-Junior C.M., Batista A.C., et al. Eosinophil depletion protects mice from tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide // Histol Histopathol. 2014. Vol. 29, N 3. P. 387–396. doi: 10.14670/HH-29.387</mixed-citation></citation-alternatives></ref><ref id="B202"><label>202.</label><citation-alternatives><mixed-citation xml:lang="en">Chouliaras K, Tokumaru Y, Asaoka M, et al. Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer. Surgery. 2021;169(5):1234–1239. doi: 10.1016/j.surg.2020.07.052</mixed-citation><mixed-citation xml:lang="ru">Chouliaras K., Tokumaru Y., Asaoka M., et al. Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer // Surgery. 2021. Vol. 169, N 5. P. 1234–1239. doi: 10.1016/j.surg.2020.07.052</mixed-citation></citation-alternatives></ref><ref id="B203"><label>203.</label><citation-alternatives><mixed-citation xml:lang="en">Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi: 10.3389/fimmu.2018.01474</mixed-citation><mixed-citation xml:lang="ru">Buder-Bakhaya K., Hassel J.C. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond // Front Immunol. 2018. Vol. 9. P. 1474. doi: 10.3389/fimmu.2018.01474</mixed-citation></citation-alternatives></ref><ref id="B204"><label>204.</label><citation-alternatives><mixed-citation xml:lang="en">Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015; 21(24):5453–5459. doi: 10.1158/1078-0432.CCR-15-0676</mixed-citation><mixed-citation xml:lang="ru">Gebhardt C., Sevko A., Jiang H., et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab // Clin Cancer Res. 2015. Vol. 21, N 24. P. 5453–5439. doi: 10.1158/1078-0432.CCR-15-0676</mixed-citation></citation-alternatives></ref><ref id="B205"><label>205.</label><citation-alternatives><mixed-citation xml:lang="en">Martens A, Wistuba-Hamprecht K, Geukes Foppen M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908–2918. doi: 10.1158/1078-0432.CCR-15-2412</mixed-citation><mixed-citation xml:lang="ru">Martens A., Wistuba-Hamprecht K., Geukes Foppen M., et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab // Clin Cancer Res. 2016. Vol. 22, N 12. P. 2908–2918. doi: 10.1158/1078-0432.CCR-15-2412</mixed-citation></citation-alternatives></ref><ref id="B206"><label>206.</label><citation-alternatives><mixed-citation xml:lang="en">Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496. doi: 10.1158/1078-0432.CCR-16-0127</mixed-citation><mixed-citation xml:lang="ru">Weide B., Martens A., Hassel J.C., et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab // Clin Cancer Res. 2016. Vol. 22, N 22. P. 5487–5496. doi: 10.1158/1078-0432.CCR-16-0127</mixed-citation></citation-alternatives></ref><ref id="B207"><label>207.</label><citation-alternatives><mixed-citation xml:lang="en">Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9(2):115–121. doi: 10.2217/imt-2016-0138</mixed-citation><mixed-citation xml:lang="ru">Moreira A., Leisgang W., Schuler G., Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy // Immunotherapy. 2017. Vol. 9, N 2. P. 115–121. doi: 10.2217/imt-2016-0138</mixed-citation></citation-alternatives></ref><ref id="B208"><label>208.</label><citation-alternatives><mixed-citation xml:lang="en">Grisaru-Tal S, Dulberg S, Beck L, et al. Metastasis-Entrained eosinophils enhance lymphocyte-mediated antitumor immunity. Cancer Res. 2021;81(21):5555–5571. doi: 10.1158/0008-5472.CAN-21-0839</mixed-citation><mixed-citation xml:lang="ru">Grisaru-Tal S., Dulberg S., Beck L., et al. Metastasis-Entrained eosinophils enhance lymphocyte-mediated antitumor immunity // Cancer Res. 2021. Vol. 81, N 21. P. 5555–5571. doi: 10.1158/0008-5472.CAN-21-0839</mixed-citation></citation-alternatives></ref><ref id="B209"><label>209.</label><citation-alternatives><mixed-citation xml:lang="en">Van Driel WJ, Hogendoorn PC, Jansen FW, et al. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum Pathol. 1996;27(9):904–911. doi: 10.1016/s0046-8177(96)90216-6</mixed-citation><mixed-citation xml:lang="ru">Van Driel W.J., Hogendoorn P.C., Jansen F.W., et al. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response // Hum Pathol. 1996. Vol. 27, N 9. P. 904–911. doi: 10.1016/s0046-8177(96)90216-6</mixed-citation></citation-alternatives></ref><ref id="B210"><label>210.</label><citation-alternatives><mixed-citation xml:lang="en">Xie F, Liu LB, Shang WQ, et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer Lett. 2015;364(2):106–117. doi: 10.1016/j.canlet.2015.04.029</mixed-citation><mixed-citation xml:lang="ru">Xie F., Liu L.B., Shang W.Q., et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell // Cancer Lett. 2015. Vol. 364, N 2. P. 106–117. doi: 10.1016/j.canlet.2015.04.029</mixed-citation></citation-alternatives></ref><ref id="B211"><label>211.</label><citation-alternatives><mixed-citation xml:lang="en">Tan LD, Schaeffer B, Alismail A. Parasitic (Helminthic) infection while on asthma biologic treatment: not everything is what it seems. J Asthma Allergy. 2019;12:415–420. doi: 10.2147/JAA.S223402</mixed-citation><mixed-citation xml:lang="ru">Tan L.D., Schaeffer B. Alismail A. Parasitic (Helminthic) infection while on asthma biologic treatment: not everything is what it seems // J Asthma Allergy. 2019. Vol. 12. P. 415–420. doi: 10.2147/JAA.S223402</mixed-citation></citation-alternatives></ref><ref id="B212"><label>212.</label><citation-alternatives><mixed-citation xml:lang="en">Oda Y, Takahashi C, Harada S, et al. Discovery of anti-inflammatory physiological peptides that promote tissue repair by reinforcing epithelial barrier formation. Sci Adv. 2021;7(47):eabj6895. doi: 10.1126/sciadv.abj6895</mixed-citation><mixed-citation xml:lang="ru">Oda Y., Takahashi C., Harada S., et al. Discovery of anti-inflammatory physiological peptides that promote tissue repair by reinforcing epithelial barrier formation // Sci Adv. 2021. Vol. 7, N 47. P. eabj6895. doi: 10.1126/sciadv.abj6895</mixed-citation></citation-alternatives></ref></ref-list></back></article>
